
Curriculum Vitae

Judes Poirier, PhD

Place of Birth Montreal, Quebec, Canada
Office Address Douglas Institute Research Centre / Neuroscience Division
6875 LaSalle Boulevard
Verdun, Quebec, CANADA, H4H 1R3
Telephone (514) 761-6131 Ext 6153
Fax (514) 888-4094
E-mail judes.poirier@mcgill.ca

PRESENT POSITIONS

Director Molecular Neurobiology Unit, Douglas Institute
Associate Director Centre for the Studies on the Prevention of Alzheimer's disease
Douglas Institute / McGill University

Full Professor Department of Psychiatry, McGill University
and Department of Medicine, McGill University

Associate Member Department of Neurology and Neurosurgery,
McGill University

Scientific Founder Nova Molecular Inc. (1995-2002)
Technosynapse Inc. (1995-)
Spectral Neuroscience Inc. (2004-)

Member, Scientific Advisory Boards
Aging Research Institute, University of South Florida, USA
Foundation Plan Alzheimer, France
Novartis Pharma Inc. / Astra Zeneca Inc. / Lundbeck USA
Alzheimer Group USA (advisory organization to the US
Government).
Health Protection Branch, Canadian Government / EPA (USA)
Food and Safety Commission, Japanese Government
Alzheimer's Disease Research Consortium of California, USA
Pfizer Inc. / Debios Pharma

Member, Board of Directors
Collège de l'Assomption (President, Board of directors)
Spectral Neuroscience Inc. (CSO/ Founder)
Alzheimer's Society of Montreal (Member / Past)

EDUCATION

- 1979-1982 University of Montreal
B.Sc. in Biochemistry
- 1983-1984 Clinical Research Institute of Montreal, University of Montreal
M.Sc. in Neurochemistry
- 1985-1987 Clinical Research Institute of Montreal, University of Montreal
Ph.D., Neurotoxicology and Neurochemistry
- 1987-1989 University of Southern California, Los Angeles, CA, USA.
Research Associate, *Molecular Neurobiology*

CURRENT APPOINTMENTS

- 1999- Full Professor, McGill University, Departments of Psychiatry and
Medicine, Montreal, Canada
- 1989- Associate Member, Department of Neurology
and Neurosurgery and Centre on Aging, McGill University

PAST APPOINTMENTS

- 2003-2008 “**Chercheur Chevronné et Émérite**” de l’Institut Canadien de Recherche sur le
Vieillessement, CIHR. (Senior Scientist, CIHR)
- 1998-2003 **Scientist**, Canadian Institute on Health Research
- 1997-2008 Director, Centre for Studies in Aging, McGill University
- 1997-2007 Director, Board of Directors, Douglas Hospital Res. Centre
- 1996- Scientific Advisor (ad hoc) for:
- Novartis, Canada and Parke-Davis USA
 - MRX Biosciences, USA, Accera Pharma, USA, Handylab, USA.
 - Nova Molecular Inc./ Spectral Neuroscience Inc.
 - Variagenics Inc., USA
 - Ebewe Pharmaceuticals and Debios Pharma, Switzerland
 - AstraZeneca, Sweden and Novartis USA.
 - Pfizer USA and Canada.
 - Aluminum Association of Canada / Rio Tinto Alcan
 - Aluminum Salts Consortium of Canada

OTHER APPOINTMENTS

Member	Editorial Board, Journal: <i>Neurobiology of Lipids</i>
Member	Editorial Board, Journal: <i>Synapse</i>
Member	Editorial Board, Journal: <i>Current Alzheimer Research</i>
Member	International Advisory Board, <i>Alzheimer Disease International</i>

GRANTING AGENCIES

Member	CIHR, Biology of Aging, CIHR (2009- Now)
Member	CIHR, Neuroscience Committee B, CIHR (2002-2005)
Member	Research Policies Committee, Alzheimer Society of Canada (1998-2001)
Member	MRCC Scholarship Committee B, MRCC (1998-2001)
Member	Canadian Foundation for Innovation, Review Board, FCAR (1998-2000) <ul style="list-style-type: none">• Chairman: Several Site Visit Committees
Member	Canadian Foundation for Innovation, Review Board, FRSQ (1998-1999)
Member	FCAR Research Centres Review Committee (1997-1999)
Chairman	Biomedical Research Council, Alzheimer Society of Canada (1995-1997)
Member	Post-Doctoral Fellowship Committee, MRCC (1994-1995)
Member	Fonds de la Recherche en Santé du Québec (1993-1994)
Member	Program Grant Review Committee, FCAR (1997-1998)

GRANTING AGENCIES: Ad hoc reviewer (active *)

1991- *	Medical Research Council of Canada / CIHR
1990- *	Alzheimer Society of Canada
1989- *	American Alzheimer Association
2001- 2008	Department of Veteran Affairs, US Government
2005-*	Welcome Trust Foundation (UK)
1990-2001	Fonds de la Recherche en Santé du Québec
1996-1997	Biomedical Research Board of Israel
1994-2000	Welcome Trust Foundation, U.K.
1994-1998	National Institute on Aging, USA
1989-1994	Parkinson Foundation of Canada
1991	Ontario Mental Health

PAST APPOINTMENTS

2008-2011	Conseiller Scientifique, Ministre des Aînés (Mrs. Blais) Québec Gouvernement.
2000-2004	Canadian Foundation for Innovation / Ministry of Education Québec Government (Director's Board)
1992-1999	Director, Aging Research Program, Douglas Hospital Research Centre, McGill University, Verdun, Canada
1996-1999	Scientific Advisory Boards: Parke-Davis, USA and Pfizer Canada.
1994-1999	Associate Professor, McGill University, Department of Psychiatry
1989-1994	Assistant Professor, McGill University, Centre for Studies in Aging
1989-1991	Assistant Professor, McGill University, Department of Medicine
1992-1994	Assistant Professor, McGill University, Department of Psychiatry
1989-1994	MRCC Scholar
1994-1998	FRSQ Scholar (Chercheur-Bourcier)
1995-1996	Member, Strategic Planning Committee ("Toward a New McGill") of the Principal, McGill University
1991-1997	Associate Director, McGill Centre for Studies in Aging
1993-1997	Co-Director, FRSQ's Alzheimer's Disease Research Consortium of Quebec
1993-1995	Member, Editorial Board, Journal: <i>Journal of Neurochemistry</i>

EXTRAMURAL GRANT SUPPORT

YEAR(S)	AWARDING INSTITUTION	TYPE OF AWARD	TOTAL AMOUNT
1989-1994	Medical Research Council of Canada (MRCC)	Scholarship	
1989-1990	Fonds de la recherche en santé du Québec	Startup Grant	\$ 25,000
1989-1990	Medical Research Council of Canada	Startup Grant	\$ 15,000
1989-1990	Parkinson Foundation of Canada <i>Antioxidants' Status in Parkinson's disease(PD)</i>	Operating Grant	\$ 28,360
1989-1991	American Health Assistance Foundation <i>Astroglial Gene Expression in Response to brain injury</i>	Operating Grant (USA)	\$157,000
1991-1992	Parkinson Foundation of Canada <i>Superoxide Dismutase Expression in Parkinson's disease</i>	Operating Grant	\$ 28,000
1991-1992	Alzheimer's Disease and Related Disorder Foundation, USA <i>Apolipoprotein E gene expression in Alzheimer's disease (AD)</i>		\$ 30,500
1991-1992	Laboratory for Disease Control, (Co-PI: Serge Gauthier) <i>Herpes Simples I and Alzheimer's disease (AD)</i>	Operating Grant	\$ 49,500
1991-1994	Fonds de la recherche en santé du Québec (FRSQ) <i>Réseau de Pharmacologie (Co-Pis: R. Quirion, B. Chan)</i>	Program Grant	\$285,000
1992-1993	Parkinson Foundation of Canada <i>Superoxide Dismutase Expression in Parkinson's disease II</i>	Operating Grant <i>(sole investigator)</i>	\$ 40,000
1992-1996	Medical Research Council of Canada <i>LDL receptor in Response to brain injury</i>	Operating Grant <i>(sole investigator)</i>	\$252,945
1992-1995	National Institute on Aging (USA) <i>Synaptic plasticity during aging and in Alzheimer's disease</i>	Operating Grant <i>(sole investigator)</i>	\$264,240
1993	Medical Research Council of Canada <i>Group grant, PI: R. Quirion</i>	Equipment Grant	\$ 98,000
1993-1994	Parkinson Foundation of Canada <i>Superoxide Dismutase Expression in Parkinson's disease III</i>	Operating Grant <i>(sole investigator)</i>	\$ 40,000
1993	Marion Merrell Dow <i>Monoamine oxidase inhibitors as growth factors</i>	Grant-in-Aid	\$ 42,000
1994-1998	Fonds de la recherche en santé du Québec	Career Award	
1994-1996	Fonds de la recherche en santé du Québec <i>(Co-PI: C. Shriqui, Laval University, Quebec, Canada)</i> <i>Antioxidants in the Treatment of Tardive Dyskinesia</i>	Operating Grant	\$102,000
1994	Eli Lilly Pharmaceutical Co. <i>Apolipoprotein E genotype and xanomeline drug response in Alzheimer's disease</i>	Grant-in-Aid	\$ 15,000
1993-1999	Fonds d'Aide aux Chercheurs et à la Recherche (FCAR) <i>Co-Pis: R. Quirion, M. Meaney</i>	Training Grant	\$330,000
1994-1998	Fonds de la recherche en santé du Québec <i>Co-PI: R. Quirion</i> <i>Alzheimer's Disease Research Consortium of the province of Quebec (32 collaborators are currently enrolled in Network)</i>	Network Grant	\$245,000 yr \$175,000 \$ 70,000
			Consortium Brain Bank

EXTRAMURAL GRANT SUPPORT (CONT'D)

YEAR(S)	AWARDING INSTITUTION	TYPE OF AWARD	TOTAL AMOUNT
1994-1997	Natural Sciences and Engineering Research Council J. (NSERC) Co-Pis: G. Massicotte, R. Quirion et al. <i>Glutamate Receptor Physiology During Aging</i>	Program Grant	\$210,900
1995-1997	Alzheimer Society of Canada (<i>Sole Investigator</i>) <i>Apolipoprotein E4, Cholinergic Dysfunction and AD</i>	Operating Grant	\$ 99,500
1995-1997	Fonds de la recherche en santé du Québec (FRSQ) <i>Probucol in the treatment of Alzheimer's disease</i>	Operating Grant	\$ 97,000
1996-1999	Pharmacia Biotechnology Inc., Sweden (<i>Sole Investigator</i>) <i>New genes associated with sporadic Alzheimer's disease</i>	Grant in Aid	\$ 250,000
1997-1999	Alzheimer Society of Canada (<i>Sole Investigator</i>) <i>Apolipoprotein E and amyloid metabolism</i>	Operating Grant	\$100,000
1997-1999	Medical Research Council of Canada (<i>Sole Investigator</i>) <i>Apolipoprotein E and cholinergic dysfunction in AD</i>	Operating Grant	\$136,080
1997-2000	Medical Research Council of Canada (<i>Sole Investigator</i>) <i>Apolipoprotein E, synaptic plasticity & Alzheimer's disease</i>	Operating Grant	\$219,480
1997-1999	Hoechst Marion Roussel, USA <i>Cholinergic dysfunction in Alzheimer's disease</i>	Grant in Aid	\$ 90,000 US
1998-2000	Medical Research Council of Canada (<i>Sole Investigator</i>) <i>Sequencing of Candidate Genes for Alzheimer's disease</i>	Operating Grant	\$ 80,045
1998-2003	Medical Research Council of Canada (<i>Sole Investigator</i>)	Scientist Award	
1999-2001	Alzheimer Society of Canada (<i>Sole Investigator</i>) <i>Apolipoprotein E and amyloid metabolism II</i>	Operating Grant	\$100,000
2000-2005	Canadian Institute of Health Research (sole investigator) <i>Apolipoprotein E, Synaptic Plasticity & Alzheimer's disease</i>	Operating Grant	\$404,075
2001-2004	Fonds d'Aide aux Chercheurs et à la Recherche (FCAR) Co-Pis: C. Ramassamy, C. Lazure and D. Averill	Team Grant	\$120,000
2001-2003	Canadian Institute of Health Research / Alzheimer's Society of Canada / Astra Zeneca (sole investigator) <i>Cholesterol Homeostasis in Alzheimer's disease</i>	Operating Grant	\$200,000
2003-2008	Canadian Institute on Health Research (CIHR) (<i>Sole Investigator</i>)	Senior Scientist Award	Career Award
2003-2005	Canadian Institute of Health Research / Alzheimer's Society of Canada / Astra Zeneca (sole investigator) <i>Cholesterol Homeostasis in Alzheimer's disease</i>	Operating Grant	\$240,000
2005-2008	Canadian Institute on Health Research (CIHR) <i>HMG CoA Reductase: A therapeutic target for the treatment of sporadic Alzheimer's disease.</i> (<i>sole investigator</i>)	Operating Grant	\$357,000
2005-2010	Fond de la Recherche en Santé du Québec Quebec Brain Bank, Director	Operating Grant	\$100,000/y

EXTRAMURAL GRANT SUPPORT (CONT'D)

YEAR(S)	AWARDING INSTITUTION	TYPE OF AWARD	TOTAL AMOUNT
2006-2008	Canadian Institute on Health Research (CIHR) Role of ApoE receptors in Sporadic Alzheimer's disease (sole investigator)	Operating Grant	\$224,000
2007-2012	Canadian Institute on Health Research (CIHR) Gene X Stress Interaction during Normal Aging in Humans (Co-PI with S. Lupien)	Operating Grant	\$415,000
2009-2014	National Science and Engineering Research council (NSERC) <i>ABC transporters function in the reinnervating brain.</i> (sole investigator)	Operating Grant	\$125,000
2011-2014	Fonds Québécois de Recherche – Nature et Technologies Prénylation dans les maladies chroniques et neurodegeneratives (Co-PIs : Y. Tsantrizos/ J. Poirier)	Operating Grant	\$225,000
2009-2014	Canadian Institute on Health Research (CIHR) <i>HMG CoA Reductase in Alzheimer's disease.</i> (sole investigator)	Operating Grant	\$675,000
2012-2017	Canadian Institute on Health Research (CIHR) <i>Characterization of newly discovered Alzheimer's disease related genes. (PI: J. Poirier plus 2 collaborators)</i>	Operating Grant	\$864,340
2012-2015	Fonds de la recherche en santé du Québec (Co-PI: Dr. J. Breitner, Quebec, Canada) <i>Biomarkers in the Prevention of common Alzheimer's disease.</i> (Co-Pi: J. Breitner and J. Poirier)	Operating Grant	\$225,000
2013	National Science and Engineering Research council (NSERC): Equipment Grant (Weiya M., Poirier J., Meaney M and Boksa P.)	Equipment Grant	\$78,654
2012-2017	Canadian Institute on Health Research (CIHR) <i>Isoprenoid cascade in Alzheimer's disease.</i> (Co-PI: Tsantrizos Y and J. Poirier)	Operating Grant	\$925,000

YEAR(S)	AWARDING INSTITUTION	TYPE OF AWARD	TOTAL AMOUNT
2013-2018	Fonds de la recherche en santé Québec (FRSQ) Consortium pour l'identification précoce de la Maladie d'Alzheimer Québec (CIMA-Q). (PI: Dr. S. Belleville / Poirier J. - Biomarker Core)	Operating Grant	\$224,000
	Canadian Institute on Health Research (CIHR) Gene X Stress Interaction during Normal Aging in Humans (Co-PI with S. Lupien)	Operating Grant	\$415,000

CAREER AND PROFESSIONAL AWARDS

1982-1985	Fellowship	La Fondation Parkinson du Québec, Québec
1985-1986	Fellowship	Phoenix Foundation, Quebec
1986-1987	Fellowship	Fonds de la recherche en santé du Québec
1987-1989	Postdoctoral Fellowship	Fonds de la recherche en santé du Québec
1989-1994	MRCC Scholarship Award	Medical Research Council of Canada
1990	Junior Fellowship	Glaxo Canada
1991	Award	Fidia/ISN
1993	Merit Award	Parkinson Foundation of Canada
1994	Claude Beaubien Award of Excellence	Alzheimer Society of Canada
1994	CCNP Investigator Award	Canadian College for Neuropsychopharmacology
1994-1998	FRSQ Career Award	Fonds de la recherche en santé du Québec
1995	ISN Young Scientist Award	International Society for Neurochemistry
1996	Parke Davis / ICAD Award	Parke-Davis Corporation International
1997	Galien Award	Pharmaceutical Manufacturer Association of Canada
1998	MRCC Scientist Award	Medical Research Council of Canada
1998	Prix André Dupont	Club de Recherches Cliniques du Québec
1998	CCNP Innovation Award	Canadian College for Neuropsychopharmacology
1999	Laurier D'Or	CLA
1999	Jonas Salk Award	March of Dime
2001/2003	Astra Zeneca Research Award	Astra Zeneca US
2001	CSCC Special Award	Canadian Society for Clinical Chemistry
2003	CIHR Senior Scientist Award	Canadian Institute on Health Research / CIA
2004	Knight, National Order of Québec	Quebec Government, Premier's Executive Council
2009	Doctor of Medicine, Honoris Causa	Faculty of Medicine, University of Montpellier, France
2010	Genesis Prize 2010	Genome Québec and BioQuébec. "Bio-innovation of the 21th Century"
2012	Hubert-Reeves Prize	Can. Association of Scientific journalists.

SPECIAL COMMUNITY-BASED RECOGNITION

1993	Neuroscientist of the year	" <i>Québec Science</i> " magazine
1995	Personality of the Year	" <i>L'actualité</i> " magazine
1996	"Who's Who in Montreal"	<i>The Gazette</i> , Newspaper
1998	Personality of the Week	" <i>La Presse</i> ", Newspaper
2000	MRCC/CIHR Ambassador for Kids	Canadian Institutes of Health Research

SUPERVISED GRADUATES/POST-DOCTORALS

M.Sc. and Ph.D. Students

1987-1989	Mr. Mark Hess, Ph.D. student in Molecular biology / Neurobiology University of Southern California
1987-1989	Miss Chris Zarrow, Ph.D. student in Neurobiology University of Southern California
1990-1991	Miss Annie Baccichet, M.Sc. student in Neurology/Neurosurgery McGill University
1991-1997	Miss Christine Tiffault, Ph.D. student, Pharmacology R. Quirion, Co-supervisor, McGill University.
1992-1999	Mr. Uwe Beffert, Ph.D. student, Neurology and Neurosurgery McGill University
1992-1994	Mr. Daniel Guillaume, M.Sc. student, Neurology and Neurosurgery McGill University
1996-2003	Danielle Champagne, Ph.D. student, Neurology and Neurosurgery McGill University
1996-1997	Brigitte Charbonneau, M.Sc. student, Neurology and Neurosurgery McGill University, Co-supervisor: J. Rochford.
1996-1999	Jean Bernard Dupuis, M.Sc. student, Psychiatry McGill University
1998-2004	Caroline Petit-Turcotte, Ph.D. student in Neurology and Neurosurgery McGill University
1999-2005	Jean-Francois Blain, Ph.D. student in Neurology and Neurosurgery McGill University
1999-2002	Roseanne Aleong, Ph.D. student in Neurology and Neurosurgery McGill University
1999-2004	Sophie Gaudrault, Ph.D. student in Neurology and Neurosurgery McGill University
2003-2008	Alexandra Fiocco, Ph.D. student in Neurology and Neurosurgery McGill University (co-supervision with S. Lupien)
2004-2009	Vanessa Pearson, Ph.D. student in Neurology and Neurosurgery McGill University
2004-2010	Stéphanie Bélanger, Ph.D. student in Neurology and Neurosurgery McGill University
2005-2008	Véronique Legault, M.Sc. student in Neuroscience Program McGill University
2009-	Valérie Leduc, MD/Ph.D. student in Neuroscience Program McGill University
2009-2011	Daphnée Lalonde, M. Sc. student in Neuroscience Program McGill University
2012 -	Justin Miron, Ph.D. student, Neuroscience Program McGill University
2012-	Patrick Gormley, M.Sc. student, Neuroscience Program McGill University

Post-Doctoral Students

1991-1995	Dr. Phillippe Bertrand, Post-Doctoral Fellow
1991-1993	Dr. Richard Alonzo, Post-Doctoral Fellow Co-supervisor: R. Quirion
1991-1994	Dr. Angèle Parent, Post-Doctoral Fellow Co-supervisor: R. Quirion
1991-1996	Dr. Satia Kar, Post-doctoral Fellow Co-supervisor: R. Quirion
1993-1995	Dr. Marie Claude Delisle, Post-doctoral Fellow
1994-1997	Dr. Marc Danik, Post-doctoral Fellow
1994-1999	Dr. Charles Ramassamy, Post-Doctoral Fellow
1994-1997	Dr. Fouad Berrada, Post-Doctoral Fellow
1995-1998	Dr. Pascale Kryskowsky, Post-Doctoral Fellow
1999- 2003	Dr. Chantal Chabot, Post-Doctoral Fellow
2007-2008	Dr. Houssein Hajj Hassan, Post-Doctoral Fellow
2008-2011	Dr. Dorothée Domenger, Post-Doctoral Fellow
2009-2012	Dr. Louis de Beaumont, Post-Doctoral Fellow
2012-	Dr. Cynthia Picard, Post-Doctoral Fellow

Invited Lecturer: National and International (since 1989)

- Nature and Nurture in the Genesis of Parkinson's Disease. Geriatric Society of America, Minneapolis, USA, October 1989, (Guest of the GSA).
- Astroglial Gene Expression During Reactive Synaptogenesis in the Human and Rodent Hippocampus. International Symposium on Alzheimer's and Parkinson's Diseases, Kyoto, Japan, November 1989, (Guest of the AHAF).
- Astroglial Gene Expression in Response to Hippocampal Deafferentation in Alzheimer's Disease. Second International Symposium on Alzheimer's Disease and Related Diseases. Toronto, Canada, July 1990, (Guest of Glaxo Pharmaceuticals).
- Gérontologie Transculturelle (Session Co-chairman), Congrès International de Gérontologie Française, Montreal, Québec, summer 1990.
- Modulation of Apolipoproteins Gene Expression and their Receptor during Reinnervation in the CNS. International Society for Neurochemistry Meeting, Sidney, Australia, July 1991, (Guest of ISN/Fidia Corp.)
- Are Free Radicals Involved in the Pathogenesis of Parkinson's Disease? 1st Sandoz Symposium of the Treatment of Parkinson's disease. Tokyo, Japan, October 1992, (Guest of Sandoz Pharmaceutical.).
- Superoxide dismutase Expression in Parkinson's Disease. Neurobiology of NOE and OHE Symposium. Washington, November 1993, (Guest of the Oxygen Society).
- Apolipoprotein E in the Injured CNS and in Alzheimer's disease. Durham, December 1993, (Guest of Duke University).
- Apolipoprotein E4 and Alzheimer's disease. Canadian Western Conference on Alzheimer's disease. Whisler, British Columbia, March 1994 (Guest of Parke-Davis Canada).
- Recent advances in the Genetic of Alzheimer's disease. Annual Meeting of the Alzheimer Society of Canada. Halifax, April 1994.

-
- Apolipoprotein E4 and cholinergic dysfunction in AD: A role for the amyloid/apoE4 complex? Springfield Meeting on Therapeutic Approaches in Alzheimer's Disease. Springfield, May 1994.
 - Predictive and diagnostic value of apolipoprotein E4 genotype in Alzheimer's Disease. Stockholm, Sweden, May 1994, (Guest of Pharmacia LKB International).
 - Apolipoprotein E, Synaptic Plasticity and Alzheimer's Disease. CCNP Meeting, Québec, Canada. May 1994.
 - Apolipoprotein E, Synaptic Plasticity and Alzheimer's Disease. MIT, Boston, USA, June 1994.
 - Apolipoprotein E Expression in the Injured CNS. Duke University Symposium. Organized by the Adler foundation. September 20, 1994. Durham. N.C., USA.
 - Apolipoprotein E, Synaptic Plasticity and Alzheimer's Disease. Columbia University, New York, New York, USA.
 - Apolipoprotein E, Synaptic Plasticity and Alzheimer's Disease. "Zurich 8" meeting on the Pharmacology of Memory Disorders Associated with Aging, Zurich, February 1995.
 - Apolipoprotein E and CNS Injuries. IPSEN Symposium on: Apolipoprotein E in Alzheimer's disease. Paris, France. May 1995. (Guest of the IPSEN Foundation)
 - Apolipoprotein E in the injured CNS and in Alzheimer's disease. International Society for Neurochemistry Meeting. Kyoto, Japan, July 1995. (Guest of the ISN)
 - Is Apo E up-regulation a viable treatment for Alzheimer's disease? Parke-Davis Symposium. Ann Arbor, Michigan, USA. October 1995. (Guest of PD, USA)
 - Rôle des apolipoprotéines dans la maladie d'Alzheimer. Congrès Francophone sur la Maladie d'Alzheimer. Lille, France. October 1995.
 - Apolipoprotein E4, synaptic plasticity and cholinergic dysfunction in Alzheimer's disease. NIH/AA Symposium of apolipoprotein E in Alzheimer's disease. Chicago, USA, October 1995.
 - Apolipoprotein E in the injured CNS and in Alzheimer's disease. Distinguished Scientists Lecture Series of the Aging Research Institute, University of South Florida, USA, January 1996. (Guest of the USF)
 - Hippocampal apolipoprotein E expression, synaptic plasticity and Alzheimers' disease. German Society for Neuroscience. Berlin, Germany. February 1996.
 - Apolipoprotein E4 modulates cholinergic activity in Alzheimer's disease and interacts with beta-amyloid to facilitate its own uptake. Nice, France, April 1996.
 - Apo E subpopulations' response to cholinomimetic drug treatments. The Hague, Netherlands, June 1996.
 - Neurobiology of apolipoprotein E in the normal and injured brain. Osaka, Japan, July, 1996
 - Apo E / Amyloid interaction in brain cell cultures. Osaka, Japan, July, 1996
 - Neurobiology of apolipoprotein E in the normal brain and in Alzheimer's disease. Mayo Clinics, Jacksonville, September 1996, USA (Guest of Mayo, Jacksonville, USA)
 - Apo E subpopulations' response to cholinomimetic drug treatments. Columbia University, New York, USA, March 1997.
 - Neurobiology of apolipoprotein E and Alzheimer's disease. IPSEN meeting, Paris, France, March 1997.
 - Neurobiology of apolipoprotein E in the normal and injured brain. University of Kuopio, Finland, March 1997. (Guest of the UK)
 - Pharmacogenetics of Alzheimer's disease. Janssen Research Institute. Gotheborg, Sweden, April 1997
 - Pharmacogenetics of Alzheimer's disease: Role of apolipoprotein E genotype. IBC conferences. San Francisco, USA, May 1997. (Guest of the IBC)
 - Apolipoprotein E4 modulates cholinergic activity and drug responsiveness in Alzheimer's disease. Leipzig, Germany. June, 1997.
 - Neurobiology of apolipoprotein E and its role in Alzheimer's disease. Pfizer Conference. IRCM, Montreal, Canada.

-
- Pharmacogenetic of Alzheimer's disease: Role of apolipoprotein E genotype. IBC Conference on Neurodegenerative diseases. Philadelphia, USA, September 1997. (Guest of the IBC)
 - Pharmacogénétique de la maladie d'Alzheimer: Rôle de l'apolipoprotéine E4. Montpellier, September 1997. (Guest of Parke-Davis, France)
 - Pharmacogenetic of apolipoprotein E and cholinergic dysfunction in Alzheimer's disease. International Conference on Aging and Dementia, Austria, October 1997. (Guest of EBEWE corp.)
 - Apolipoprotein E as a pharmacogenetic and therapeutic target for Alzheimer's disease. Alzheimer's disease: New Drug Strategies, Boston, USA, February 1998.
 - Apolipoprotein E, cholinergic integrity and amyloid metabolism in Alzheimer's disease. International Symposium of the N.Y. Academy of Science entitled: Toward a Unifying Hypothesis of Alzheimer's disease. New York, March 1998. (Guest of the NYAS)
 - Apolipoprotein E4 and cholinergic dysfunction: Implication in the treatment of Alzheimer's disease. Geneva, Switzerland, April 1998 (Guest of the Springfield Symposium).
 - Pharmacogenetics of Alzheimer's disease and the apolipoprotein E4 polymorphism. Bio 98. New York, USA, June 1998 (Guest of Variagenics Corp)
 - Apolipoprotein E: A potential therapeutic target to alleviate cholinergic deficit in Alzheimer's disease. Amsterdam, Holland, July 1998 (Guest of the Alzheimer Congress, 1998)
 - Pharmacogenetics of Alzheimer's Disease: A role for Apolipoprotein E and Butyrylcholinesterase K Polymorphisms, Tokyo, Japan, October 1998 (Guest of Annual Symposium in Neurology).
 - Pharmacogenetics in Neurology and Psychiatry. AACC Pharmacogenetics in Patients Care Conference, Chicago, USA, November 1998 (Guest of the AACC).
 - Apolipoprotein E as a pharmacogenetic and therapeutic target for the treatment of Alzheimer's disease. ACNP annual meeting, Porto Rico, December, 1998 (Guest of Eli Lilly).
 - Pharmacogénétique de la maladie d'Alzheimer : Un rôle pour l'apolipoprotéine E. IPSEN Meeting, Paris, France, January 1999. (Guest of IPSEN, France)
 - Neurobiology of Apolipoprotein E and its role in Alzheimer's disease. Gordon Conferences, Ventura, California, USA, January 1999 (Guest of the Gordon Conferences).
 - Apolipoprotein E as a pharmacogenetic and therapeutic target for Alzheimer's disease IBC Conference, on Alzheimer's disease. Boston, USA, May 1999 (Guest of the IBC Conferences).
 - Apolipoprotein E as a pharmacogenetic tools for Alzheimer's disease stratification IBC Conference, on Pharmacogenomics. Boston, USA, July 1999 (Guest of the IBC Conferences).
 - Apolipoprotein E as a pharmacogenetic tools for Alzheimer's disease stratification Otsuka Pharmaceuticals. Osaka, Japan, November 1999 (Guest of Otsuka and Fujisawa Corp.)
 - Apolipoprotein E: A therapeutic target for the treatment of Alzheimer's disease. 7 th Springfield Symposium on the Treatment of Alzheimer's disease. Stockholm, Sweden. April 2000 (Guest of the Springfield Symposium)
 - Apolipoprotein E: A therapeutic target for the treatment of Alzheimer's disease. World Congress on Alzheimer's Disease 2000. Washington, USA. July 11, 2000. (Guest of the World Congress)
 - Apolipoprotein E: A pharmacogenetic and therapeutic target for the treatment of Alzheimer's disease Janssen Medical Institute, Goteborg, Sweden, September 2000 (Guest of Janssen Institute)
 - Apolipoprotein E: A pharmacogenetic and therapeutic target for the treatment of Alzheimer's disease . International Conference on Alzheimer's and Parkinsons's disease, Kyoto, Japan , March 2001 (Guest of International Conference).
 - Neurobiology of apolipoprotein E : From Pharmacogenomics to Therapeutic Applications. The 2001 Gowdey Lecturer of the department of pharmacology, University of Western Ontario. London.
 - Apolipoprotein E: A pharmacogenetic and therapeutic target for the treatment of Alzheimer's disease

-
- (Plenary Lecture 2001) American Association for Clinical Chemistry, Chicago, July 2001 (Guest of AACC and CACC, USA).
- Cholesterol transport and synthesis is abnormal in Alzheimer's disease. 8th Springfield Symposium on the Treatment of Alzheimer's disease. Geneva, Switzerland. April 2002 (Guest of the Springfield Symposium)
 - Cholesterol transport and synthesis is abnormal in Alzheimer's disease. World Congress on Alzheimer's Disease 2002. Stockholm, Sweden. July 24, 2002. (Guest of the World Congress)
 - Cholesterol transport and synthesis as therapeutic targets for the treatment of Alzheimer's disease. Max Plank Institute International Congress on "Cell and Molecular Biology of Alzheimer's Disease". Hamburg, Germany, September 9-11, 2002. (Guest of the Congress)
 - Cholesterol transport and synthesis as therapeutic targets for the treatment of Alzheimer's disease. International Congress on Alzheimer's and Parkinson's Disease. Seville, Spain, May 3-11, 2003.
 - Cholesterol metabolism as therapeutic targets for the treatment of Alzheimer's disease. International Advisory Board of Pfizer Pharmaceutical (CNS), August 26-28, 2003, Gothenburg, Sweden. (Guest of Pfizer Pharma Europe)
 - Cholesterol transport and synthesis is abnormal in Alzheimer's disease. Neurobiology of Aging Symposium. New Orleans, USA. November 5, 2003. (Guest of the Symposium organizing committee)
 - Cholesterol metabolism as therapeutic targets for the treatment of Alzheimer's disease. 9th International Springfield/Montreal Symposium on the Treatment of Alzheimer's disease. Montreal, Canada. April 2004 (Guest of the Springfield Symposium)
 - Poirier J. (2004) ApoE and HMG CoA Reductase: Genetic Risk Factors and Therapeutic Targets for Sporadic Alzheimer's Disease. Novartis Symposium on Alzheimer's Disease Therapy. New York, NY, November 2004, USA.
 - Poirier J. (2005) ApoE and HMG CoA Reductase: Genetic Risk Factors and Therapeutic Targets for Sporadic Alzheimer's Disease. International Alzheimer's and Parkinson's diseases Congress, Sorrento, Italy, 2005. (Guest of the Congress).
 - Poirier J. (2005) Apolipoprotein E4: A target for developing new therapeutics for Alzheimer's disease. International Conference on Cholesterol, Statins and Alzheimer's disease, Stockholm, Sweden, Spring 2005. (Guest of the conference organizer)
 - Poirier J. (2005) Frontiers in Drug discovery: Targeting Apolipoprotein E. AMRI International Conference on Drug Development. Albany, NY, USA (Guest of the organizers). Fall 2005.
 - J. Poirier, D., Dea, N. Aumont, L. Lamarre-Thérroux, V. Pearson and S. Bélanger. (2006) Targeting apolipoprotein E And Its Main Receptors With Pharmacological Modulators Of Cholesterol Homeostasis In Alzheimer's Disease. 10th International Springfield/Geneva Symposium on the Treatment of Alzheimer's disease. Geneva, Switzerland. April 2006 (Guest of the Springfield Symposium)
 - Cholesterol transport and synthesis in common Alzheimer's disease (2006). World Congress on Alzheimer's Disease 2006. Madrid Spain. July 20, 2006. (Guest of the World Congress)
 - Poirier J., Leduc V., Dea D. and Thérroux L. (2007) AD/PD 2007. Apolipoprotein E4 and Paraoxonase 1 genetic variations affect both risk levels and cholinergic system integrity in the human brain with Alzheimer's disease. World Congress on Alzheimer's and Parkinson's Disease. Salzburg, Austria, March 2007 (Guest of the World Conference).
 - Cholesterol transport and synthesis in common Alzheimer's disease (2007). Leon Thal Conference on Alzheimer's Disease Therapy. Lou Ruvo Institute

-
- Las Vegas, USA (Guest of the Ruovo Institute)
- Poirier J. (2008) Perspective on the role of public / private partnerships in the development of novel experimental therapies for Alzheimer's disease. Leon Thal Conference on Alzheimer's Disease Therapy. Lou Ruovo Institute, Las Vegas, USA (Guest of the Ruovo Institute)
 - Poirier J., Legault V., Dea D. and Thérroux L. (2009) AD/PD 2009. HMG Coa Reductase: Genetic risk factor and modulator of Alzheimer's disease pathophysiology. World Congress on Alzheimer's and Parkinson's Disease. Prague, Tscheck Republic, March 2009, (Guest of the World Conference).
 - Poirier J. (2009) Apolipoprotein E induction as a potential therapeutic target for the treatment of sporadic Alzheimer's disease. Pfizer Research Headquarter, Groton, Connecticut, USA. (Guest).
 - Poirier J. (2009) Apolipoprotein E induction as a potential therapeutic target for the treatment of sporadic Alzheimer's disease. Montpellier University, France (Guest).
 - Butyrylcholinestase pharmacogenomics and Alzheimer's disease (2010). World Congress on Alzheimer's Disease 2010. Hawaii, USA. July 12, 2010 (Guest of the ICAD congress).
 - Poirier J. (2011) Progress in the field of Alzheimer's disease: A review of France's recent accomplishments. Paris, France (Guest of La Fondation du Plan Alzheimer, France).
 - Poirier J. (2012) Developmental neurotoxicity of aluminum salts in the diet: A Public Health Assessment. Ministry of Health, Tokyo, Japan. (Guest of the Food and Safety Commission of Japan).
 - Poirier J. (2012) Biomarqueurs, Génétique et Pharmacogénomique dans la Prévention et le Traitement de la Maladie d'Alzheimer. Lyon, France. (Guest of the Entretiens Jacques-Cartier – Canada/France)
 - Y.S. Tsantrizos,*§ J.W. De Schutter,§ A. Langille,§ Y.-S. Lin and Poirier J. (2013) AD/PD 2013: Isoprenoid Pathway Involvement in Sporadic Alzheimer's Disease. World Congress on Alzheimer's and Parkinson's Disease. Florence, Italy, March 2013, (Guest of the World Conference).
 - Poirier J. (2013) Genomics of Unhealthy Aging: Clues from Alzheimer's disease. 21st International Congress of Genetics. Singapore, Singapore. (Guest of HUGO and Genome Canada).
 - Poirier J. (2013) Apolipoprotein E, Cholesterol and Cardiovascular Factors in the Etiology of Alzheimer's Disease: Myths and Reality. International Conference on Nutrition and the Brain 2013. Washington, USA (Guest of the Organizing Committee).

SYMPOSIUM / MEETING ORGANIZATION

Symposium: Apolipoprotein E and Cholesterol Homeostasis in Alzheimer's disease, Geneva, Spring 2002. As part of the 5th International Conference on Advances in Alzheimer's disease.

Symposium: Emerging Therapies for the Treatment of Alzheimer's disease, Montreal, Spring 2003. As part of the CCNP Annual Conference.

Co-organizer and Host of the ***9th Springfield/Montreal International Conference on Advances in Alzheimer's disease (April 2004: 750 participants)***

Symposium: Role of Apolipoprotein E and Cholesterol Synthesis in the Pathogenesis of Alzheimer's disease, Montreal, ***Spring 2004. As part of the 6th Montreal/Springfield International Conference on Advances in Alzheimer's disease.***

Symposium: Cholesterol Homeostasis and the Pathogenesis of Alzheimer's disease, Geneva, ***Spring 2006. As part of the 10th Geneva/Springfield International Conference on Advances in Alzheimer's disease.***

PROFESSIONAL SOCIETIES and CONSORTIUMS

- ◆ International Society for Neurochemistry
- ◆ Society for Neurosciences
- ◆ American Association for Advancement of Science

- ✚ Member of the JPND – BIOMARKADPD consortium (Europe/North America)
- ✚ Consortium pour l'identification précoce de la Maladie d'Alzheimer - Québec (CIMA-Q)

PUBLICATIONS

1. Poirier J., Donaldson J. and Barbeau A. (1985) The specific vulnerability of substantia nigra is related to the presence of transition metals. *Biochem. Biophys. Res. Comm.* 128 (1) : 25-33
2. Poirier J. and Barbeau A. (1985) A catalyst function for MPTP in superoxide formation. *Biochem. Biophys. Res. Comm.* 131 (3) : 1284-1289
3. Poirier J. and Barbeau A. (1985) 1-methyl-4-phenyl pyridinium-induced inhibition of NADH cytochrome reductase. *Neurosci. Lett.* 62 (1) : 7-15
4. Barbeau A., Dallaire L., Buu N.T., Poirier J. and Rucinska E. (1985) Comparative behavioral, biochemical and pigmentary effects of MPTP, MPP+ and Paraquat in *Rana Pipiens*. *Life Sci.* 37 : 1529-1538
5. Barbeau A., Cloutier T., Roy M., Plasse L., Paris S. and Poirier J. (1985) Eco-genetic of Parkinson's disease : The 4-hydroxylation of debrisoquine. *Lancet* 2 : 1213-1216
6. Barbeau A., Roy M., Cloutier T., Masson H., Bernier G., Dallaire L. and Poirier J. (1985) Eco-genetics of Parkinson's disease : Genetic susceptibility. *Neurology* 36 : 201
7. Barbeau A., Dallaire L. and Poirier J. (1986) Animal models and pathophysiology of CNS degenerative disorders. *Integrative Psychiatry* 4:75-78
8. Poirier J. and Barbeau A. (1987) Erythrocyte antioxidant activities in patients with Parkinson's disease. *Neurosci. Lett.* 75:345-348
9. Poirier J. (1987) Pathophysiology and biochemical mechanisms involved in MPTP-induced parkinsonism. *J. Am. Geriatr. Soc.* 35 (7) : 660-668
10. Poirier J. and Barbeau A. (1987) MPTP potentiates iron-induced lipid peroxidation without the involvement of free radicals derived from oxygen. *Res. Comm. Chem. Pathol. Pharmacol.* 56 (3) : 387-401
11. Poirier J., Roy M., Campanella G., Cloutier T. and Paris S. (1987) Debrisoquine metabolism in parkinsonian patients treated with antihistaminic drugs. *The Lancet* 2 : 396
12. Pasinetti G.M., Morgan D.G., Lerner S.L., Poirier J. and Finch C.E. (1989) In Situ hybridization histochemistry technique: An approach to the pharmacology of tyrosine hydroxylase mRNA gene expression. *Pharmacol. Research* 21: 299-311
13. May P.C., Johnson S.A., Poirier J. and Finch C.E. (1989) Altered gene expression in Alzheimer's disease brain tissue. *Can. J. Neurol. Sci.* 16: 473-476
14. Poirier J., May P.C., Osterburg H.H., Geddes J. Cotman C.W. and Finch C.E. (1990) Alteration of gene expression in rat hippocampus following entorhinal cortex lesions. *Proc. Natl. Acad. Sci.* 87: 303-307
15. May P.C., Lampert-Etchells M., Johnson S.A., Poirier J., Masters J.N. and Finch C.E. (1990). Dynamics of gene expression for a hippocampal glycoprotein elevated (Apo J) in Alzheimer's disease and in response to experimental lesions in the rats. *Neuron* 5: 831-839
16. Poirier J., Hess M., May P.C. and Finch C.E. (1991) Cloning of hippocampal poly(A)RNA sequences that increase after entorhinal cortex lesion in adult rat. *Mol. Brain Res.* 9: 191-195
17. Poirier J. Kogan S. and Gauthier S. (1991) Environment, genetics and idiopathic Parkinson's Disease *Can. J. Neurol. Sci.* 18: 70-76
18. Poirier J., Hess M., May P.C. and Finch C.E. (1991) Apolipoprotein E- and GFAP-RNA in hippocampus during reactive synaptogenesis and terminal proliferation. *Mol. Brain Res.* 11: 97-106
19. Poirier J. and Nichol N.R. (1991) Alteration of hippocampal RNA prevalence in response to deafferentation *Meth. Neurosci.* 7: 182-199

20. Poirier J., Baccichet A., Dea D. and Gauthier S. (1992) Glucocorticoid modulation of alpha₁-tubulin and gamma-actin gene expression during hippocampal reactive synaptogenesis in adult rats. *Mol. Brain Res.* 15: 263-268
21. Poirier J., Baccichet A., Dea D. and Gauthier S. (1993) Role of hippocampal cholesterol synthesis and uptake during reactive synaptogenesis in adult rats. *Neuroscience* 55: 81-90
22. Parent A., Dea D., Quirion R. and Poirier J. (1993) [3H]Phorbol ester binding sites and neuronal plasticity in the hippocampus following entorhinal cortex lesions. *Brain Res.* 607: 23-32
23. Poirier J. and Thiffault C. (1993) Are free radicals involved in the pathophysiology of Parkinson's Disease. *Eur. Neurol.* 33:38-43
24. Kar S., Baccichet A., Quirion R. and Poirier J. (1993) Entorhinal cortex lesion induces differential responses in [125I]IGF I, [125I]IGF II and [125I]Insulin receptor binding sites in the rat hippocampal formation. *Neuroscience*, 55: 69-80.
25. O'Donnell D., Baccichet A., Seckl J.R., Meaney M.J. and Poirier J. (1993) Entorhinal cortex lesions alter glucocorticoid but not mineralocorticoid receptor gene expression in the rat hippocampus. *J. Neurochem.* 61: 356-359
26. Bertrand P., Guillaume D., Hellauer K., Dea D., Lindsay J., Kogan S., Gauthier S. and Poirier J. (1993) Distribution of Herpes virus Type I DNA in selected areas of normal and Alzheimer's disease brains: A PCR study. *Neurodegeneration* 2: 201-208.
27. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P. and Gauthier S. (1993) Apolipoprotein E phenotype and Alzheimer's Disease. *Lancet* 342: 697-699.
28. Aubert I., Poirier J., Gauthier S. and Quirion R. (1994) Multiple Pre- and Post-synaptic Cholinergic Markers are not Altered in the Rat Dentate Gyrus Following Entorhinal Cortex Lesioning: An Established Model of Acetylcholine Esterase Neuronal Plasticity *J. Neurosci.* 14: 2476-2484
29. Parent A., Poirier J., Baccichet A. and Quirion R. (1994) Regulation of 1,4,5-IP₃, 1,3,4,5-IP₄ and IP₆ binding sites following entorhinal cortex lesions in rat brain. *Neuroscience* 61:565-573.
30. Poirier J., Baccichet A., Dea D. and Thiffault (1994) Superoxide dismutase expression in the nigrostriatal pathway in idiopathic parkinson's disease. *Ann. N.Y. Acad. Sci.* 738: 116-122.
31. Nalbantoglu J., Gilfix B.M., Bertrand P., Robitaille Y., Gauthier S., Rosenblatt D.S. and Poirier J. (1994) Predictive value of apolipoprotein E4 mutation in Alzheimer's Disease. *Ann. Neurol.* 36: 889-895.
32. Alonzo R., Poirier J., O'Donnell D., Buisson N., Dorio J., Boksa P. (1994) Statin, a marker of cell cycle arrest, is overexpressed during the early phase of delayed NMDA toxicity in hippocampal cell cultures. *Mol. Cell. Neurosci.* 5: 530-539.
33. Poirier J. (1994) Apolipoprotein E in animal models of brain injury and in Alzheimer's Disease. *Trends Neurosci.* 12: 525-530.
34. Bertrand P., Oda T., Finch C.E., Pasinetti G.M. and Poirier J. (1995) Association between apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer's disease. *Mol. Br. Res.* 33; 174-178
35. Thiffault C., Aumont N., Quirion R. and Poirier J. (1995) Effect of MPTP and L-Deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. *J. Neurochem.* 65: 2725-2733
36. Poirier J., Aubert I., Quirion R., Farlow M., Nalbantoglu J., Gilfix B.G. and Gauthier S. (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. *Proc. Natl. Acad. Sci.* 92: 12260-12264.
37. Poirier J., Beffert U., Alonzo R., Dea D., Baccichet A. and Boksa P. (1996) Increased levels of statin, a marker of cell cycle arrest, in response to hippocampal neuronal injury *Mol. Br. Res.* 34: 57-64
38. Beffert U. and Poirier J. (1996) Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. *Ann. N.Y. Acad. Sci.* 777: 166-174.

39. Poirier J., Minnich A. and Davignon J. (1996) Apolipoprotein E, synaptic plasticity and Alzheimer's disease. *Annals of Medicine*: 27: 663-670.
40. Poirier J. (1996) Apolipoprotein E in the brain and its role in Alzheimer's disease. *J. Psychiatr. Neurosci.* 21: 128-134.
41. Tanzi R. Breitner J. Farrer L. Gandy S. Haines J. Hyman B. Mullan M. Poirier J. Strittmatter W. Folstein M. Farlow M. Mayeux R. Petersen R. Roses A. Schenk D. Small G. Vangool W. Cookdeegan R. Fleck L. Kapp M. Karlinsky H. Pericakvance M. Post S. Wolpert C. et al. (1996) Apolipoprotein E genotyping in Alzheimer's disease. *Lancet.* 347 : 1091-1095
42. Poirier J. (1996) Role of apolipoprotein E during synaptic remodelling and in Alzheimer's disease. *Dementia* 10: 136-145.
43. Gauthier S. and Poirier J. (1996) The common sense approach to Alzheimer's disease *Patient Care*: 7: 26-39
44. Guillaume D., Bertrand P., Dea D., Davignon J. and Poirier J. (1996) Apolipoprotein E and low-density lipoprotein internalization in primary cultures of rat astrocytes: Isoform-specific alterations. *J. Neurochem.* 66: 2410-2418.
45. Gauthier S., Montplaisir J., Petit D., Joannette Y., Feldman H., Mohr E. and Poirier J. (1996) Outcome variables in presymptomatic individuals at higher risk of developing Alzheimer's disease. *Alzheimer Dis. Related Disorders* 10: 19-21.
46. Farlow M.R., DeBomoy L.K., Poirier J., Davignon J. and Hui Siu (1996) Apolipoprotein E genotype and gender influence response to Tacrine therapy. *Ann N.Y. Acad. Sci.* 802: 101-110.
47. Thiffault C., Lamarre-Théroux L., Quirion R. and Poirier J. (1997) Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse. *Mol. Br. Res.* 44: 238-244.
48. Nalbantoglu J., Tirado-Santiago G., Lahsaini A., Poirier J., Goncalves O., Verge G., Momoli F., Massicotte G., Julien J.P. and Shapiro M.L. (1997) Impaired spatial learning and long-term potentiation in transgenic mice expressing the C-terminal fragment of the Alzheimer amyloid precursor protein. *Nature* 387:500-507
49. Gauthier S., Panisset M., Nalbantoglu J. and Poirier J. (1997) Alzheimer's disease: current knowledge, management and research. *Can J. Med. Assoc.* 157: 1047-1052.
50. Thiffault C. Quirion R. Poirier J. (1997) The effect of l-deprenyl, d-deprenyl and MDL72974 on mitochondrial respiration - a possible mechanism leading to an adaptive increase in superoxide dismutase activity. *Molecular Brain Research.* 49(1-2):127-136
51. The apo E and Alzheimer's disease meta-analysis consortium (1997) Effect of age, gender and ethnicity on the association of apolipoprotein E genotype and Alzheimer's disease. *J.A.M.A.* 278: 1349-1356
52. Beffert U., Aumont N., Dea D., Davignon J., Lussier-Cacan S. and Poirier J. (1998) Apolipoprotein E uptake is increased by beta-amyloid peptides and reduced by blockade of the LDL receptor in neurons. *J. Neurochem.* 70: 1458-1466.
53. Farlow M., Lahiri D.K., Poirier J., Schneider L., Hui S.L. (1998) Treatment outcome of tacrine therapy depends on apolipoprotein E genotype and gender of the subject with Alzheimer's disease. *Neurology* 50: 669-677.
54. Beffert U., Danik M., Krzywkowski P., Ramassamy C., Berrada F. and Poirier J. (1998) Neurobiology of apolipoproteins and their receptors in the CNS and in Alzheimer's disease. *Brain Research Reviews* 27: 199-142.
55. Lambert J.C., Berr C., Pasquier F., Delacourte A., Frigard F., Cotel D., Pérez-Tur J., Mouroux V., Mohr M., Cécyre D., Galasko D., Poirier J., Hardy J, Mann D. , Amouyel P. and Chartier-Harlin M.C. (1998) Pronounced impact of Th1/E47cs mutation compared to -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's Disease. *Hum. Mol. Genetic* 7: 1511-1516.

56. Beffert U. Bertrand P. Champagne D. Gauthier S. Poirier J. (1998) HSV-1 in brain and risk of Alzheimers Disease. *Lancet*. 351 :1330-1331.
57. Thiffault C., Quirion R. and Poirier J. (1998) Effect of MAO-B inhibitor, MDL 72974 on superoxide dismutase activity and lipid peroxidation levels in the mouse brain. *Synapse* 28: 208-211.
58. Danik M. and Poirier J. (1998) Apolipoprotein E and neuronal plasticity following experimental deafferentation and in Alzheimer's disease. *Biochemical Soc. Trans.* 26(2): 262-266
59. Beffert U. Bertrand P. Champagne D. Gauthier S. Poirier J. (1998) HSV-1 in brain and risk of Alzheimers Disease. *Lancet*. 352: 238 (letter).
60. Beffert U. and Poirier J. (1998) Apolipoprotein E associated with lipid has a reduced capacity to inhibit beta amyloid fibrill formation. *Neuroreport* 9: 3321-3323.
61. Poirier J. and Sevigny P. (1998) Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. *J. Neural Transm.* (53):199-207, 1998
62. Terrisse L. Poirier J. Bertrand P. Merched A. Visvikis S. Siest G. Milne R. Rassart E. (1998) Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients. *J. of Neurochemistry*. 71(4):1643-1650.
63. Poirier J. (1998) Apolipoprotéine E4, intégrité du système cholinergique et pharmacogénétique de la maladie d'Alzheimer. *Médecine Sciences Suppl.* 2: 3-9.
64. Beffert U., Arguin C. and Poirier J. (1998) The polymorphism in exon 3 of the low density lipoprotein receptor-related protein gene is weakly associated with Alzheimers disease. *Neurosci. Lett.* 258: 1-4.
65. Weibush H., Sheppard K., Poirier J. and Sévigny P. (1999) Synergistic association between apoE epsilon 4 and BCHE-K allele in confirmed Alzheimers disease. *Hum. Genetics* 104: 1-6.
66. Poirier J. (1999) Apolipoprotein E4, cholinergic Integrity and the pharmacogenetic of Alzheimers disease. *J. Psychiatry and Neuroscience* 24: 147-153
67. Beffert U., Bertrand P., Champagne D., Gauthier S. and Poirier J. (1999) Herplex simplex 1 in brain, apolipoprotein E genotype and Alzheimer Disease. *M. J. Medecine* 4: 4-8.
68. Krzywkowski P., Gagne J, Chabot C., Kar S., Rochford J., Massicotte G. and Poirier J. (1999) Cholinergic system and long term potentiation in memory-impaired apolipoprotein E deficient mice. *Neuroscience* 92: 1273-1283.
69. Beffert U., Aumont N., Dea D., Lussier-Cacan Suzanne, Davignon J. and Poirier J. (1999) Apolipoprotein E isoform specific reduction of extracellular amyloid in neuronal cultures. *Mol. Br. Res.* 68: 181-185.
70. Bastianetto S., Ramassamy C., Poirier J. and Quirion R. (1999) Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. *Mol Br. Res.* 66: 35-41.
71. Terisse L, Séguin D., Bertrand P., Poirier J., Milne R. and Rassart E. (1999) Modulation of apolipoprotein D and apolipoprotein E expression in the rat hippocampus in the rat hippocampus after entorhinal cortex lesions. *Mol. Br. Res.* 70: 26-35
72. Beffert U., Cohn J.S., Petit-turcotte C., Tremblay M., Aumont N., Ramassamy C., Davignon J. and Poirier J. (1999) Apolipoprotein E and Beta amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent . *Brain Res.* 843: 87-94.
73. Ramassamy C., Averil D., Beffert U., Bastianetto S., Thérroux L., Lussier Cacan S., Cohn J.S., Christen Y., Davignon J., Quirion R. and Poirier J. (1999) Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. *Free Rad. Biol. Med.* 27: 102-112.
74. Poirier J. (1999) Apolipoprotein E: A pharmacogenetic target for the treatment of Alzheimer's disease. *Molecular Diagnosis* 4: 335-341.
75. Bretsky P.M., Buckwalter J.G., Seeman T.E., Miller C.A., J. Poirier, Shellenberg G.D., Finch C.E. and

- Henderson V.W. (1999) Evidence for interaction between apolipoprotein E, genotype, gender and Alzheimer's disease. *Alz. Dis. Assoc. Dis.* 13: 216-221.
76. Ramassamy C., Averill, D., Beffert U., Th  roux, L., Lussier-Cacan S., Cohn J.S., Christen Y., Schoofs A., Davignon J. and Poirier J. (2000) Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain. *Neurobiol. Dis.* 7: 23-37.
77. Patrick CB, Krzywkowski P, Ramassamy C, Poirier J, Rapoport SI, Murphy EJ. (2000) Phospholipase A(2) activity is decreased selectively in the hippocampus of aged apolipoprotein E deficient mice. *Neuroscience Letters.* 288(3) : 211-214.
78. Bastianetto S., Ramassamy C., Dor   S., Christen S., Poirier J and Quirion R. (2000) The ginkgo biloba extract EGB 761 protects hippocampal neurons against cell death induced by beta amyloid. *Eur. J. Neurosci.* 12 : 18882-18890.
79. Valastro B., Ghribi O., Poirier J., Krzywkowski P. And Masicotte G. (2001) AMPA receptor regulation and LTP in the hippocampus of young and aged apolipoprotein E-deficient mice. *Neurobiol. Aging* 22(1):9-15.
80. Danik M., Champagne D., Petit-Turcotte C., Beffert U. and Poirier J. (2000) Brain lipoprotein metabolism and its relation to neurodegenerative disease. *Critical Reviews Neurobiol.* 13: 357-407.
81. Poirier J. (2001) Apolipoprotein E and Alzheimer's disease. *Ann. N.Y. Acad. Sci.* 972: 81-92.
82. Ramassamy C., Krzywkowski P., Averill D., Lussier-Cacan S., Theroux L., Christen Y., Davignon J. and Poirier J. (2001) Impact of apoE deficiency on oxidative insults and antioxidants levels in the brain. *Mol. Br. Research* 86: 76-83.
83. Lehmann DJ, Wiebusch H, Marshall SE, Johnston C, Warden DR, Morgan K, Schappert K, Poirier J, Xuereb J, Kalsheker N, Welsh KI, Smith AD. (2001) HLA class I, II & III genes in confirmed late-onset Alzheimer's disease. *Neurobiology of Aging*, 22(1): 71-77.
84. Vaucher E., Aumont N., Pearson D., Rowe W., Poirier J. and Kar S. (2001) Amyloid beta peptide levels and its effects on hippocampal acetylcholine release in aged, cognitively impaired and unimpaired rats. *J. Chem. Neuroanat.* 21: 323-329.
85. De Leon M.J., A. Convit, O.T. Wolf, C.Y. Tarshish, S. DeSanti, H. Rusinek, W. Tsui, E. Kandil, A. J. Scherer, A. Roche, A. Imossi, E. Thorn, M, Bobinski, C. Caraos, P. Lesbre, D. Schlyer, J. Poirier, B. Reisberg and J. Fowler (2001). Prediction of cognitive decline in normal elderly subjects with FDG-PET. *Proc. Natl. Acad. Sci.* 98: 10966-10871.
86. Petit-Turcotte, C., S.M. Stohl, U. Beffert, J.S. Cohn, N.Aumont, M.Tremblay, D.Dea, J. Poirier and N.S. Shachter. Apolipoprotein C-I expression in the brain in Alzheimer's disease (2002). *Neurobiol. Dis.* 8: 953-963.
87. Poirier J. (2002) High blood pressure and apolipoprotein E4: A true synergistic effect on late life cognitive function. *Stroke* 32: 2888-2889.
88. Poirier J. (2002) Evidence that clinical effects of cholinesterase inhibitors are related to potency and targeting of action. *Int. J. Clin.Pract.* 118: 6-19.
89. Zetterberg H., Palmer M., Ricksten A., Poirier J., Palmqvist L., Rymo L., Zafiroopoulos A., Arvanitis D. A., Spandidos D. A., and Blennow K. (2002) Influence of the apolipoprotein E varepsilon 4 allele on human embryonic development. *Neurosci Lett* 324, 189-192.
90. Poirier. J. and Panisset (2002) Apolipoprotein E: A novel therapeutic target for the treatment of Alzheimer's disease . *Adv. Behav. Biol.* 51: 39-43.
91. Champagne D., Dupuy J.B., Rochford J. and Poirier J. (2002) Detailed analysis of learning strategies in three versions of the Morris water maze task that differentially promote the use of allocentric and egocentric navigation in apolipoprotein E knockout mice. *Neuroscience* 114: 641-654.

92. Aleong R., Aumont N., Crews B., Marnett L. and Poirier J. (2003) Non-steroidal anti-inflammatory drugs mediate increased in vitro glial expression of apolipoprotein E protein – implications for the treatment of Alzheimer's disease *Eur. J. Neurosci.* 18: 1428-1438
93. de Leon M., Segal S., Tarshish C., DeSanti S., Caraos C., Saint Louis L.A, Qadri I F., Lesbre P., Wisniewski T., Poirier J, and Davies J. (2003) Longitudinal Tau Levels Increase in Mild Cognitive Impairment. *Neurosci. Lett.* 333:183-186.
94. Champagne D., Pearson D., Dea D., Rochford J and Poirier J. (2003) Cholesterol lowering drug Probucol increases apolipoprotein E production in the hippocampus of aged rats: implication for Alzheimer's disease. *Neuroscience* 121: 99-110.
95. Poirier J. (2003) Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. *Trends Mol. Medicine* 9: 94-101
96. Poirier J. (2003) The importance of acetylcholinesterase and butyrylcholinesterase in dementia. *Geriatrics and Aging* 6: 6-10.
97. Evans R.M., Hui S., Perkins T, Lahiri D., Poirier J., Hendrie H.C. and M.R. Farlow (2004) Cholesterol and APOE genotype Interact to Influence Alzheimer's Disease Progression. *Neurology* 2004;62:1869–1871.
98. Blain J.F., Paradis E., Gaudreault S.B., Champagne D., Richard D. and Poirier J. (2004) A role for lipoprotein lipase during synaptic remodelling in the adult mouse brain. *Neurobiol. Dis.* 15: 510-516.
99. Gaudreault S., Chabot C., Gratton J.P. and Poirier J. (2004) The Caveolin Scaffolding Domain Modifies AMPA Receptor Binding Properties by Inhibiting PLA2 Activity *J. Biol. Chem.* 279: 356-362.
100. Gaudreault S., Dea D. and Poirier J. (2004) Increased caveolin-1 expression in Alzheimer's disease brain. *Neurobiol. Aging* 25: 753-759.
101. Blain J.F. and Poirier J. (2004) Could Lipoprotein Lipase Play a Role in Alzheimer's Disease? *TSWJ Cell Biol.* 4: 531-535
102. Blain J.F. and Poirier J. (2004) Cholesterol homeostasis and the pathophysiology of Alzheimer's disease. *Expert Rev. Neurotherapeutics* 4(5): 823-829.
103. Poirier J. (2005) Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. *Neurobiol. Aging* . 26: 355-361
104. Turcotte C., Aumont N., Beffert U., Dea D. and Hertz J.(2005) The apoE receptor apoER2 is involved in the maintenance of efficient synaptic plasticity. *Neurobiol. Aging.* 26: 195-206.
105. Gaudreault S., Blain J.F., Gratton J.P. and Poirier J. (2005) A Role for Caveolin-1 in Post-Injury Reactive Neuronal Plasticity. *J. Neurochem.* 92: 831-839.
106. Champagne D., Rochford J. and Poirier J. (2005) Effect of Apolipoprotein E Deficiency on Reactive Sprouting in the Dentate Gyrus of the Hippocampus Following Entorhinal Cortex Lesion: Role of the Astroglial Response. *Exp. Neurol.* 194: 31-42.
107. Kar S., Poirier, J., Dea D and Quirion R. (2006) Cellular distribution of insulin-like growth factor-II/mannose-6-phosphate receptor in normal human brain and its alteration in Alzheimer's disease pathology. *Neurobiol Aging.* 27: 199-210.
108. Blain J.F., Sullivan P.M. and Poirier J. (2006) A deficit in astroglial organization causes the impaired reactive sprouting in human apolipoprotein E4 targeted replacement mice. *Neurobiol Dis.* 21(3): 505-514.

109. Hirsch-Reinshagen V., Blain J.F., Poirier J. and Wellington C. (2006) The absence of ABCA1 decreases soluble apoE levels but does not diminish amyloid deposition in two murine models of Alzheimer's Disease. *J. Biol. Chem.* 280: 43243-43256.
110. Blain J.F., Aumont N., Th  roux L., Dea D. and Poirier J. (2006) Intronic polymorphisms of the lipoprotein lipase are associated with the risk and pathology of common Alzheimer's Disease. *Eur. J. Neurosci.* 24 (5): 1-5.
111. Turcotte C., Aumont N., Blain J.F. and Poirier J. (2007) Synaptic plasticity in the CNS require amyloid peptides, apoE and its receptors apoER2 and LRP. *Neuroscience* 150: 58-63.
112. Fiocco A.J., Joober R., Poirier J. and Lupien S. (2007) Polymorphism of the 5HT2A Receptor Gene: Association with Stress-Related Indices in Healthy Baby Boomers. *Front. Behavior. Neurosci.* 1 (3): 1-7.
113. Aleong R., Aumont N., Blain J.F. and Poirier J. (2008) Pro-inflammatory cytokines mediate in vitro glial expression of apolipoprotein E protein – implications for the treatment of Alzheimer's disease. *Curr. Alz. Dis.* 5: 33-37.
114. Poirier J. and Gauthier S. (2008) Pharmacogenomics and the Treatment of Sporadic Alzheimer's Disease: A Decade of Progress. *Curr. Pharmacogen. Pers. Med.* 6: 63-76.
115. Poirier J. (2008) Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer's disease *Alz. Dem.* 4: 91- 97.
116. Gauthier S. and Poirier J. (2008) Current and future management of Alzheimer's disease. *Alzheimer Dem.* 4: 48-50.
117. Leduc V., Th  roux L. and Poirier J. (2008) Polymorphisms at the PON1 L55M and Q192R loci affect the pathophysiology of Alzheimer's disease: emphasis on the cholinergic system and beta-amyloid levels. *Neurodegenerative Dis.* 5: 225-227.
118. Fiocco A., Poirier J. and Lupien S. (2008) Acute and Long-Term Associations Between ApoE Genetic Polymorphism, Cortisol Levels and Declarative Memory Performance in Older Adults *Psychoneuroendocrinology* 33: 625-633.
119. Khachaturian Z.S., Petersen R.C., Gauthier S, Buckholtz S, Corey-Bloom J.P, Reisberg B, Aisen P.S., Poirier J. et al. (2008) A roadmap for the prevention of dementia. *Alz. Dem.* 4 (3):156-63.
120. Burgess B., Parkinson P.F., Hirsch-Reinshagen V. Theroux L., Poirier J. and Wellington C.L. (2009) influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. *J. Lipid. Res.* 49:1254-1267.
121. Freemantle E., Vandal M., Tremblay-Mercier J., Poirier J. and Cunnane S. (2009) Metabolic response to a ketogenic breakfast in the healthy elderly. *J. Nut. Health and Aging* 13 (4) 293-298.
122. Rajah, M.N., Bastianetto S., Bromley-Brits, K., Cools R. Grady, C. Poirier, J., Quirion, R. Song, W., Pruesner, J. (2009) Biological changes associated with healthy versus pathological aging: A symposium review. *Aging Res. Rev.* 8 (2) 140-146.
123. Gauthier S. and Poirier J. (2009) Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium." Who may benefit from disease-modifying studies in Alzheimer's disease? *Alzheimer Dem.* 5:147-148
124. Khachaturian, Z. S., Snyder, P. J., Doody, R., Aisen, P., Comer, M., Dwyer, J., Frank, R. A., Holzapfel, A., Khachaturian, A. S., Korczyn, A. D., Roses, A., Simpkins, J. W., Schneider, L.




- S., Albert, M. S., Egge, R., Deves, A., Ferris, S., Poirier, J. et al. (2009). A roadmap for the prevention of dementia II: Leon Thal Symposium . *Alzheimer Dem.* 5: 85-92.
125. Fiocco A.J., Lupien S., Poirier J. (2009) A three-year longitudinal study of genetic influence on basal cortisol levels, cognitive performance, and psychological factors in healthy older adults *Neurobiol. Aging.* 30 (6): 1001-1005.
126. Leduc V., Dea. D. , Robitaille Y. and Poirier J. (2010) Involvement of Paraoxonase 1 genetic variants in Alzheimer's disease neuropathology. *Eur. J. Neurosci.* 30: 1823-1830.
127. Leduc V., Jasmin-Bélanger, S. and Poirier J. (2010) Apolipoprotein E and cholesterol homeostasis in Alzheimer's disease. *Trends Mol. Med.* 16: 469 – 477.
128. Andersen S. and Poirier (2011) Pharmacogenetic analysis of the effects of polymorphisms in IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study. *BMC Medical Genetics* 12: 137-148.
129. Leduc V., Legault V, Dea D and Poirier J. (2011) Reference genes for the normalization of expression in human brain tissues using SYBR green qPCR: A Case for Paraoxonase 1 and 2. *J. Neurosci. Meth.* 200 (1): 14-19.
130. Leduc V., Domenger,D., De Beaumont, L. Lalonde, D., Bélanger-Jasmin, S. and Poirier J. (2011) Function and Comorbidities of Apolipoprotein E in Alzheimer's Disease. *Int. J. Alzheimer's Disease* 94: 1-22.
131. Poirier J. Semple H., Davies J. Lapointe R., Dziwenka M., Hiltz M. and Mujibi D. (2011) Double-blind, vehicle-controlled randomized twelve month neurodevelopmental toxicity study of common aluminum salts in the rat. *Neuroscience* 193: 338-62.
132. De Beaumont L., Tremblay S. Poirier J., Lassonde M and Théoret H. (2012). Altered bidirectional plasticity and reduced implicit motor learning in concussed athletes. *Cerebral Cortex* 22: 112—121
- 133: Poirier J, Leduc V. and De Beaumont L. (2012) Apolipoprotein E4: From genetic risk factor to synaptic modulator in both familial and sporadic Alzheimer's disease. *BMC Alz. Res. Ther.* (under review).
134. Domenger D, Dea D., Theroux L, Moquin L, Gratton A and Poirier J. (2012) The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain. *Exp. Neurology* 2012 Jan; 233(1):513-22.
135. Aleong R., Domenger D and Poirier J. (2012) Pro-inflammatory cytokines and anti-inflammatory drugs modulate glial expression of apolipoprotein E protein. *Adv. Alz. Research* 1: 154-171
- 136: Tremblay S., De Beaumont L, Evans A.C., Poirier J. and Lassonde M (2013) Sports concussions and aging: a neuroimaging investigation *Cerebral Cortex* 23: 1159-1166.
- 137: Bélanger Jasmin S., Pearson V., Lalonde D., Domenger D., Théroux L. and Poirier J. (2013) ABC transporters ABCA1 and ABCG1 gene expression and Liver-X receptor involvement during synaptic remodeling in response to entorhinal cortex lesion in the adult mouse. *J. Neurochem.* (under review, *J. Neurochem*)
- 138: De Beaumont L., Fiocco, A., Quesnel, G., Lupien S. and Poirier J. (2013) Altered declarative memory in introverted middle-aged adults carrying the BDNF val66met allele. *Behav Brain Res* (in press)

- 139: De Beaumont, L., Legault V., Lamarre-Théroux L., Dea D., Leduc V., Aumont N., Robitaille Y., Aisen, P., Petersen R.C., the Alzheimer's Disease Neuroimaging Initiative and Poirier J. (2013) HMG CoA reductase is a genetic modifier for risk, age of onset and conversion in Alzheimer's disease in a triple-cohort study. (PNAS, second round of reviews).
- 140: De Beaumont, L., Dea D., Lamarre-Théroux L., Aisen P., Petersen R.C. and the ADCS Butyrylcholinesterase K is a catalyst for MCI conversion and a potent pharmacogenomic modulator of cognitive performance. (Submitted, Neurology).

BOOKS

Judes Poirier (Ed.). Apoptosis: Techniques and Protocols. (1997). Neuromethods # 29, Humana Press. New York. 286 pages.

Judes Poirier and Serge Gauthier. La Maladie D'Alzheimer: Un Guide (2011). Librex, Montreal. 191 pages.

-  German translation 2013
-  Adaptation for France 2013
-  Chinese translation 2015

BOOK CHAPTERS

- 1) Poirier J., Dallaire L. and Barbeau A. (1986)
Parkinson's Disease and Free Radicals. In : Free radicals , cell damage and disease. Ed. Catherine Rice-Evans. Richelieu Press, London. Pp. 273-293
- 2) Barbeau A., Dallaire L., Poirier J., Rucinska E., Buu N.T. and Donaldson J. (1986)
Studies on MPTP, MPP+ and Paraquat in frog and in vitro. In : MPTP: A neurotoxin producing a parkinsonian syndrome. S.P. Markey, N. Castagnoli, A. Trevor and J.I. Kopin (Eds). Academic Press, New York. Pp. 85-103
- 3) Poirier J. and Finch C.E. (1989)
Neurochemistry of the Aging Human Brain in : Principles of Geriatric Medicine and Gerontology (2nd Ed.), W.R. Hazzard, R. Andres, E.L. Bierman and J.P. Blass. McGraw Hill : New York. Pp. 905-912
- 4) Poirier J., Hess M., May P.C., Pasinetti G. and Finch C.E. (1990)
Astroglial gene expression during reactive synaptogenesis in: Basic and Therapeutic Strategies in Alzheimer's and Parkinson's diseases. Plenum Press, New York. pp. 191-194.
- 5) Meaney M.J., Bodnoff S.R., Bhatnagar S., O'Donnell, D., Welner S.A. and Poirier J. (1997).
Adrenal glucocorticoids as modulators of brain aging in: M.H. Markham and G.B. Stefano (Eds.) Model Systems: Neuroregulatory Mechanisms in Aging. Manchester University Press, (in press)
- 6) Poirier J. and Finch C.E. (1993)
Neurochemistry of the aging human brain in : Principles of Geriatric Medicine and Gerontology (3rd Ed.), W.R. Hazzard, R. Andres, E.L. Bierman and J.P. Blass. McGraw Hill : New York. pp. 1105-1112.
- 7) Kar S., Quirion R., Baccichet A. and Poirier J. (1993)
IGF-I, IGF II and Insulin Receptor binding sites in the rat hippocampal formation: topographic distribution and response to entorhinal cortex ablation in: Growth Factors, Peptides and Receptor, T.W. Moody, Ed., New York, Plenum Press, 265-277.
- 8) Poirier J., Aubert I., Bertrand P., Quirion R. Gauthier S. and Nalbantoglu J. (1994)
Apolipoprotein E4 and cholinergic dysfunction in AD: A role for the amyloid/apoE4 complex? in: Alzheimer's disease: Therapeutic Strategies. Eds. E. Giacobini and R.E. Becker. Birkhauser, Boston. pp. 72-76.
- 9) Guillaume D., Dea D., Davignon J. and Poirier J. (1994)
Low-density lipoprotein pathways in the CNS and apolipoprotein E isoform-specific differences in: Research Advances in Alzheimer's disease and related disorders (Eds K. Iqbal J.A. Mortimer, B. Windblad and H. M. Wisniewski, J. Wiley and Sons, pp. 385-395.
- 10) Poirier J., Nalbantoglu J., Guillaume D. and Bertrand P. (1995)
Apolipoprotein and Alzheimer' disease in: Pathobiology of Alzheimer's disease. Eds A. Goate and F. Ashall. Academic Press, London pp. 225-245
- 11) Delisle M.C. and Poirier J. (1996)
Neurotransmitter in the Aging Brain. in: Encyclopedia of Aging. Second Edition (Ed. S.W. Sussman). Springer Publishing Co. pp. 684-686.

- 12) Poirier J., Delisle M.C., Quirion R., Aubert I., Rocheford J. Rouse I., Gracon S., Farlow S. and Gauthier S. (1996) Apolipoprotein E4, cholinergic integrity, synaptic plasticity and Alzheimer's disease in: Apolipoprotein E and Alzheimer's disease. (Eds. A. Roses, K. Wesgraber and Y. Christen). Springer-Verlag, Paris pp. 20-28.
- 13) Blass J. and Poirier J. (1996)
Pathophysiology of Alzheimer's disease in: Clinical Diagnosis and Management of Alzheimer's disease (Ed. S. Gauthier), Martin Dunitz Press. London. 17-31
- 14) Beffert U., Aumont N., Dea D., Davignon J. and Poirier J. (1996)
Apolipoprotein E uptake is increased by beta-amyloid peptides and reduced by blockade of the LDL receptor in: Neurodegenerative Diseases. Ed. G. Fiskum, Plenum Press, New York. Pp. 103-107
- 15) Gauthier S. and Poirier J. (1997)
Alzheimer's Disease in: Neuroprotection in CNS diseases. Eds. T. Beal and J. Beal, Marcel Dekker, New York. Pp. 447-456.
- 16) Gauthier S., Poirier J. and Gray J. (1997)
Effects on decline or deterioration in: Alzheimer's Disease: From Molecular Biology to Therapy. (R. Becker and E. Giacobini, eds). Birkhauser, Boston. pp 382-385.
- 17) Poirier J., Aubert I., Quirion R., Gauthier S., Farlow M., Nalbantoglu J., Delisle M.C. and Gracon S. (1997) Apolipoprotein E4 and cholinergic activity in Alzheimer's disease in: Alzheimer's Disease: From Molecular Biology to Therapy. (R. Becker and E. Giacobini, eds). Birkhauser, Boston. pp 55-60.
- 18) Poirier J. (1997)
Neurobiology of apolipoprotein E in the normal brain and in Alzheimer's disease in: Alzheimer's disease: Biology, diagnosis and Therapeutics (Eds K. Iqbal, B. Windblad, M. Takeda and H. M. Wisniewski, J. Wiley and Sons. New York. Pp. 93-101.
- 19) Boksa P., Beffert U., Alonzo R., O'Donnell D. and Boksa P. (1997)
Statin, a marker of cell cycle arrest, that is up-regulated in response to hippocampal neuronal injury in: Apoptosis: Techniques and Protocols, Ed. J. Poirier, Humana Press. New York. pp. 161-182.
- 20) Schneider L., Farlow M.R., Pogoda J.M. and Poirier J. (1997)
Interaction of estrogen replacement therapy and apolipoprotein E genotype status on response to cholinesterase inhibitor therapy in Alzheimer's disease in: Alzheimer's disease: Biology, diagnosis and Therapeutics (Eds K. Iqbal, B. Windblad, M. Takeda and H. M. Wisniewski, J. Wiley and Sons. New York. Pp. 655-659.
- 21) Quirion R., Auld D., Beffert U., Poirier J. and Kar S. (1998)
Putative links between some key pathological features of the Alzheimer's brain. In: The Aging Brain. Eds E. Wang and S. Snyder. Academic Press, New York. Pp. 181-198.
- 22) Poirier J. (1998) Pharmacogenetic approach to the treatment of Alzheimer's disease: Role of apolipoprotein E genotype. In Alzheimer's Disease II. IBC Library Series. Pp. 22-31.
- 23) Poirier J. (1998) Apolipoprotein E as a risk factor for Alzheimer's disease in: Heterogeneity of Alzheimer's Disease (Eds A. Wallin, K. Blennow and B. Eriksson). Janssen Medical Institute Publications, pp. 13-15.
- 24) Poirier J. and Sevigny P. (1998) Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease in: Aging and Dementia. Eds K. Jellinger, F. Fazekas and M. Windicsh.

-
- Springer Wien, New York. Pp 199-207.
- 25) Gauthier S. and Poirier J. (1998) Achievements and Unresolved Issues in Alzheimer's Disease in: Pharmacotherapy of Alzheimer's disease (Ed. S. Gauthier). Martin Dunitz, New York. Pp. 151-158.
 - 26) Ramassamy C., Krzykowski P., Bastianetto S., Averill D., Christen Y., Quirion R. and J. Poirier (1998) Apolipoprotein E, oxidative stress and Ginkgo biloba extract 761 in Alzheimer's disease in: Ginkgo Biloba extract (EGB 761): Lessons from cell biology. Eds L. Packer and Y. Christen. Elsevier. Pp. 69-83.
 - 27) Bastianetto S., Ramassamy C., Christen Y., Poirier J. and Quirion R. (1998) Ginkgo biloba extract (EGB 761) prevents cell death induced by oxidative stress in hippocampal neuronal cell culture in: Ginkgo Biloba extract (EGB 761): Lessons from cell biology. Eds L. Packer and Y. Christen. Elsevier. Pp. 85-99.
 - 28) Poirier J., Danik M. and Blass J.P. (1999) Pathophysiology of Alzheimer's disease. in: Clinical Diagnosis and Management of Alzheimer's Disease. 2nd Edition. Ed. S. Gauthier. Martin Dunitz, London. Pp. 17-32.
 - 29) Gauthier S., Panisset M. and Poirier J. (1999) Démence de type Alzheimer in: Précis pratique de Gériatrie. Ed. A. Hebert. EDISEM. Paris. Pp. 174-181.
 - 30) Poirier J., Dea D. and Danik M. (1999) Genetics of Alzheimer's disease in: An Atlas of Alzheimer's Disease. Ed. M.J. DeLeon. Parthenon Publishing Group, New York. Pp. 131-142.
 - 31) Poirier J. (2000)
L'apolipoprotéine E : une cible pharmacogénétique et thérapeutique pour le traitement de la maladie d'Alzheimer de type sporadique in: Le Maladie d'Alzheimer: Prédiction, Prévention et Prise en Charge. Eds. F. Forette, Y. Christen et F. Boller. Publications FNG. Pp. 111-123.
 - 32) Petit-Turcotte C and Poirier J. (2001) Neurotransmitter in the Aging Brain. in: Encyclopedia of Aging: The Comprehensive Resource in Gerontology and Geriatrics. Third Edition (Ed. G.L. Maddox). Springer Publishing Co. Pp. 343-346.
 - 33) Schappert K., Sevigny P. and Poirier J. (2002)
Apolipoprotein E: A pharmacogenomic marker used in the treatment of Alzheimer's disease in: Pharmacogenetics of Psychotropic Drugs (P. Lerer, ed.), Cambridge University Press, London pp. 358-369.
 - 34) Poirier J. (2002) Cholesterol transport and synthesis are compromised in the brain in sporadic Alzheimer's Disease: From risk factors to therapeutic targets in: Alzheimer's Disease and Related Disorders Annual, Eds. S. Gauthier and J.E. Cummings. Dunitz Press . pp. 1-23.
 - 35) Poirier J. (2003) Apolipoprotein E, cholesterol lowering drugs and HMG CoA reductase in sporadic Alzheimer's disease. In: Alzheimer's disease: Biology, diagnosis and Therapeutics (Eds K. Iqbal, B. and Windblad), J. Wiley and Sons. New York, Pp. 468-478.
 - 36) Belanger S., Pearson V. and Poirier J. (2006) Pathophysiology of Alzheimer's disease. in: Clinical Diagnosis and Management of Alzheimer's Disease. 3rd Edition. Ed. S. Gauthier. Informa, London. Pp. 15-26
 - 37) Gauthier S. and Poirier J. (2006) Maladie D'Alzheimer in: Précis Pratique de Gériatrie. 2^{ème} Ed. A. Hebert. EDISEM. Paris. 54-64.
 - 38) Poirier J. (2006) Apolipoprotein E4: From synaptic remodeling to genetic risk factor in both familial and sporadic Alzheimer's disease in: Alzheimer's Disease : 100 years and Beyond. Jucker, M.; Beyreuther, K.; Haass, C.; Nitsch, R.M.; Christen, Y. (Eds.) Springer/Fondation IPSEN. Paris. 289-294.

-
- 39) Poirier J. (2007) Apolipoprotein E: a potent gene-based therapeutic target for the treatment sporadic Alzheimer's disease. In: *Pharmacological and Mechanisms in Alzheimer's Therapeutic*. C. Cuello (Ed.). Springer, New York. Pp. 212-222.
 - 40) Poirier J. (2007) Cholesterol Transport and Production In Alzheimer's Disease in: *Advances In Behavioral Biology*, Vol. 57, Eds. A. Fisher and I. Hanin. Plenum Publishers. Pp 101-106.
 - 41) Leduc V., Théroux L. and Poirier J. (2008) Polymorphisms at the PON1 L55M and Q192R loci affect the pathophysiology of Alzheimer's disease: emphasis on the cholinergic system and beta-amyloid levels. in: *Advances In Behavioral Biology*, Eds. A. Fisher, Windish M. and I. Hanin. Plenum. pp. 45-49.

ABSTRACTS

- 1) Barbeau A., Poirier J., Dallaire L., Rucinska E., Buu N.T. and Donaldson J. (1985) Studies on MPTP, MPP+ and Paraquat in frogs and in vitro. Symposium on MPTP, Bethesda, USA, 1985
- 2) Poirier J., Dallaire L. and Barbeau A. (1985) Parkinson's disease and free radicals. International Symposium of the Society for Free Radical Research London, December 1985
- 3) Poirier J. and Barbeau A. (1986) Mode of action of MPTP and analogs. *Trans. Am. Soc. Neurochem.* 14 : 292
- 4) Barbeau A., Roy M., Dallaire L. and Poirier J. (1986) MPTP and environmental factors in Parkinson's disease. *Trans. Am. Soc. Neurochem.* 17 : 104
- 5) Poirier J. and Barbeau A. (1987). MPTP potentiates iron-induced lipid peroxidation in intact cells J.. *Neurochem.* 48: S159
- 6) Poirier J., May P.C. and Finch C.E. (1988) Alteration in glial fibrillary acidic protein mRNA content in the rat hippocampus after entorhinal cortex lesion. *Society for Neuroscience Abstr.* 14: 897
- 7) May P.C., Lampert-Etchell M., Poirier J. and Finch C.E. (1988) Characterization of pADHC9-1: A poly(A)RNA sequence overexpressed in Alzheimer's disease hippocampus. *Alzheimer Dis. Associated Disorder* 2: 204
- 8) Hess M., Poirier J., May P.C. and Finch C.E. (1989) Temporally regulated changes in alpha¹-tubulin and apolipoprotein E mRNA's following entorhinal cortex lesion in the rats. *Society for Neurosci. Abstr.* 15: 91.
- 9) Poirier J., Hess. M., May P.C., Pasinetti G. and Finch C.E. (1989) Astroglial Gene Expression During Reactive Synaptogenesis in the Human and Rodent Hippocampus. *International Symposium on Alzheimer's and Parkinson's diseases, Kyoto, Japan, 1989.*
- 10) Poirier J. (1989) Nature and Nurture in the Genesis of Parkinson's disease. *American Geriatric Society, Minneapolis, USA.*
- 11) Baccichet A., Dea D, May P.C., Finch C.E and Poirier J.. (1990) Astroglial gene expression in response to hippocampal deafferentation in Alzheimer's disease. *Proceeding of the Second International Symposium on Alzheimer's disease and related diseases. Toronto, Canada, July 1990*
- 12) Poirier J. Baccichet A. and Dea D. (1991) Modulation of apolipoprotein E gene expression and its receptor during reactive synaptogenesis in the hippocampus. *Proceeding of the International Society for Neurochemistry Meeting, Sidney, Australia, July 1991 (J. Neurochem. 57: S90C).*
- 13) Baccichet A., Dea D. and Poirier J. (1991) Modulation by glucocorticoids of apolipoprotein E gene expression in the regenerating hippocampus. *Proceeding of the meeting of International Brain Research Organization, Montreal, Canada, August 1991*
- 14) Dea, D., Baccichet A. and Poirier J. (1991) Gene expression of apolipoprotein E / apolipoprotein B (LDL) receptor in the hippocampus following deafferentation. *Proceeding of the International Brain Research Organization Symposium, Montreal, Canada, August 1991*
- 15) Dea, D., A. Baccichet and Poirier J. (1991) Glucocorticoid modulation of apolipoprotein E and LDL receptor expression in the hippocampus during reactive synaptogenesis. *Soc. Neurosci. Abstr.* 17: 737
- 16) Baccichet A. Dea D. and Poirier J. (1991) Altered cholesterol metabolism during reactive synaptogenesis in the deafferented hippocampus. *Soc. Neurosci. Abstr.* 17: 336
- 17) Poirier J., Parent A.R., Baccichet A. and Quirion R. (1991) Protein kinase C binding sites during neuronal plasticity following entorhinal cortex lesions in rat. *Soc. Neurosci. Abstr.* 17: 736
- 18) Aubert I., Poirier J., Baccichet A. and Quirion R. (1991) Muscarinic receptor subtypes and other cholinergic markers are differentially affected in the rat dentate gyrus following entorhinal cortex lesions. *Soc. Neurosci. Abstr.* 17: 736.
- 19) Parent A., Poirier J., Brooks W., Allaoua H. and Quirion R. (1992) Protein kinase C, inositol phosphates and neuronal plasticity. *Proceedings of the CCNP, Saskatoon, Canada.*

- 20) Poirier J. and Gauthier S. (1992) Ambiente, genetica e parkinsonismo idiopatico. Update Parkinson Dis. 2: 15-16

ABSTRACTS (CONT'D)

- 21) Kar S., Quirion R., Baccichet A. and Poirier J. (1992) [125I]IGF I, [125I]IGF II and [125I]Insulin Receptor Binding Sites in the Rat Hippocampal Formation: Topographic Distribution and Response to Entorhinal Cortex Lesions in: Proceedings of the Peptide and Growth Factors Meeting, Washington, May 1992.
- 22) Poirier J., Bertrand P., Alonzo R., Quirion R. and Boksa P. (1992) Neuronal cells in primary culture exhibit LDL receptor-mediated endocytosis of lipoproteins: A role in CNS cholesterol metabolism. Soc. Neurosci. Abstr. 18: 788
- 23) Aubert I., Poirier J., Baccichet A., Gauthier S. and Quirion R. (1992) Nicotinic acetylcholine receptors are decreased in the rat dentate gyrus following entorhinal cortex lesions. Soc. Neurosci. Abstr. 18: 788
- 24) Gauthier S., Parent A.R., Dea D., Quirion R. and Poirier J. (1992) Inositol phosphate binding sites and neuronal plasticity following entorhinal cortex lesioning. Soc. Neurosci. Abstr. 18: 607
- 25) Thiffault C., Aumont N., Quirion R. and Poirier J. (1992) Effect of Deprenyl and MPTP on superoxide dismutase activity in the striatum of C57/BL6 mice. Soc. Neurosci. Abstr. 18:1247
- 26) Baccichet A., Thiffault C., Aumont N., Dea D. and Poirier J. (1992) Superoxide Dismutase expression in the nigro-striatal pathway of patients with Parkinson's disease. Soc. Neurosci Abstr. 18: 1247
- 27) O'Donnell D., Aumont N., Baccichet A., Seckl J.R., Poirier J. and Meaney M. (1992) Entorhinal cortex lesions produce changes in glucocorticoid but not mineralocorticoid receptor gene expression. Soc. Neurosci. Abstr. 18: 1483
- 28) Dea D., Baccichet A., Bertrand P. and Poirier J. (1992) LDL receptor expression during synaptic remodelling in the hippocampus following entorhinal cortex lesioning. Soc. Neurosci. Abstr. 18: 607
- 29) Poirier J., Alonso R., Baccichet A., Dea D., O'Donnell D. and Boksa P. (1993) Statin, a cell cycle arrest marker, is increased in Ca1 neurons of the hippocampus in Alzheimer's disease and in entorhinal cortex lesioned rats. Soc. Neurosci. Abstr. 19: 884
- 30) Beffert U., Baccichet A., Dea D. and Poirier J. (1993) Statin, a cell cycle arrest marker, is up regulated following intra hippocampal colchicine in the rat. Soc. Neurosci. Abstr. 19: 884
- 31) Alonso R., Poirier J., Dea D. Baccichet A. Quirion R and Boksa P. (1993) Statin, a cell cycle arrest marker, is overexpressed in during neuronal injury in hippocampal cell culture. Soc. Neurosci. Abstr. 19: 884.
- 32) Poirier J. (1993) Statin, a cell cycle arrest marker, is overexpressed in response to neuronal injury. Proceedings of the CCNP/BAP, Montreal, June 1993.
- 33) Alonso R., Poirier J., Boksa P. and Quirion R. (1993) Statin, a marker of cell cycle arrest, is overexpressed during neuronal injury in hippocampal cell cultures. Proceeding of the CCNP/BAP, Montreal, June 1993)
- 34) Poirier J., Thiffault C. and Quirion R. (1993) Superoxide Dismutase Expression in Parkinson's Disease Conference on the Neurobiology of OHE and NOE National Institute of Health, Washington, November, 1993.
- 35) Bertrand P., Dea D., Baccichet A. and Poirier J. (1993) Glucocorticoid impairment of hippocampal reactive synaptogenesis : Correlation with the cholesterol metabolism. J. Neurochem. 61: 152
- 36) Poirier J. (1994) Apolipoprotein E and Alzheimer's disease. Western Canadian Conference on Alzheimer's Disease. Vancouver, March, 1994.
- 37) Poirier J. (1994) Apolipoprotein E4 and Cholinergic Dysfunction In AD: A Role for the β -amyloid/ApoE4 Complex?, Springfield, USA, May 1994.
- 38) Poirier J. (1994) Apolipoprotein E, Synaptic plasticity and Alzheimer's disease. CCNP, Canada
- 39) Poirier J., Guillaume D., Dea D. and Davignon J. (1994) Low-density lipoprotein pathways in the CNS

and apolipoprotein E isoform-specific differences. Fourth International Conference on Alzheimer's disease and Related Disorders. Minneapolis, August 1994, USA.

ABSTRACTS (CONT'D)

- 40) Walker M., Steverman W., Rowe W., Poirier J., Quirion R. and Meaney M. (1994) Correlation between individual performance in a test of spatial memory and hippocampal neuronal pathology in aged rats. Soc. for Neurosci. Abstr. 20: 391.
- 41) Thiffault C., Quirion R. and Poirier J. (1994) Antioxidant enzymes in an animal model of Parkinson's disease. Soc. Neurosci. Abstr. 20: 1464.
- 42) Poirier J. (1995) Apolipoprotein E in the injured CNS and in Alzheimer's disease. International Society for Neurochemistry Meeting, Kyoto, Japan, July 1995
- 43) Dea D. Bertrand P., Pasinetti G.M., Finch C.E., Terisse L., Rassart E. and Poirier J. (1995) Association of apolipoprotein E genotype with brain levels of apolipoprotein E, J, and D in Alzheimer's disease. International Society for Neurochemistry Meeting, Kyoto, Japan, July 1995.
- 44) Beffert U., Aumont N., Dea D., Davignon J., and Poirier J. (1995) Apolipoprotein E and beta-amyloid interactions in neurons and astrocytes in culture. Neurodegenerative diseases 95: Washington, USA
- 45) Poirier J. (1995) Apolipoprotein E in the injured CNS and in Alzheimer's disease. IPSEN Meeting, Paris, May 1995.
- 46) Poirier J. (1995) Rôle de l'apolipoprotéine E4 dans la maladie d'Alzheimer. Congrès Francophone sur la maladie d'Alzheimer. Lille, France, October 1995.
- 47) Poirier J. (1995) Is apo E up-regulation in the brain a viable treatment for Alzheimer's disease? Parke-Davis Symposium. Ann Arbor, Michigan, USA. October 1995.
- 48) Apolipoprotein E4, synaptic plasticity and cholinergic dysfunction in Alzheimer's disease. NIH/AA Symposium of apolipoprotein E in Alzheimer's disease. Chicago, USA, October 1995.
- 49) Poirier J., Dea D., Aumont N., Quirion R., Aubert I., Davignon J., Beffert U. And Farlow M. (1996) Hippocampal apolipoprotein E expression, synaptic plasticity and Alzheimer's disease. German Society for Neuroscience, Berlin, February 1996.
- 50) Poirier J., Quirion R., Rochford J., Gracon S., Farlow, M. and Gauthier S. (1996) Apolipoprotein E4 and cholinergic activity in Alzheimer's disease. Springfield Meeting on Alzheimer's disease Therapies, Nice, April 1996, France.
- 51) Gracon S., Poirier J., Schneider L., Farlow M., Berghoff T and Soon M. (1996) The impact of apolipoprotein E genotype on treatment response to Tacrine: Primary efficacy measures, nursing home placement and mortality. Lancet Conference, Edinburgh, Scotland, April 1996
- 52) Poirier J. (1996) Role de l'apolipoprotéine E4 dans la maladie d'Alzheimer : Impact sur le traitement. Congrès de Neurologie, Juin 1996, Paris, France.
- 53) Poirier J. (1996) Cholinergic dysfunction in Alzheimer's disease: A role for apolipoprotein E4. European Neurology Congress, The Hague, June 1996.
- 54) Poirier J. (1996) Neurobiology of apolipoprotein E in the normal brain and in Alzheimer's disease. 5th International Meeting on Alzheimer's disease and Related Disorders. Osaka, August 1996, Japan.
- 55) Bastionetto S., Ramassamy C., Quirion R. and J. Poirier (1996) Neurosteroids and Ginkgo Biloba extract prevent cell death induced by hydrogen peroxide in hippocampal neuronal cell cultures. Soc. Neurosci. Abstr. 26:1919
- 56) Beffert U., Faure M.P., Aumont N., Dea D. and Poirier J. (1996) Apolipoprotein E uptake and degradation in primary cultures of neurons and astrocytes. Soc. Neurosci. Abstr. 26: 2117
- 57) Ramassamy C., Bastianetto S., Dea D., Schoofs A., Christen Y. And Poirier J. (1996) Consequences of oxidative stress on the levels of apolipoprotein E and J in cultured astrocytes. Soc. Neurosci. Abstr. 26: 206.
- 58) Krzywkowski P., Mololi F., Rochford J., Gauthier S. And Poirier J. (1996) Cholinergic systems in apolipoprotein E knockout mice. 26: 206.

- 59) Danik M., Dea D. and Poirier J. (1996) Sequence determination of the LDL receptor gene in Alzheimer's disease subjects. Soc. Neurosci. Abstr. 26: 208

ABSTRACTS (CONT'D)

- 60) Kar S., Beffert U., Dore S., Robitaille Y., Sly W.S., Poirier J. and Quirion R. (1996) Presence of insulin-like growth factor II receptors in the neuritic plaques of Alzheimer's disease brain. Soc. Neurosci. Abstr. 26: 1175
- 61) Auld D.S., Beffert U., Kar S., Aumont N., Poirier J. and Quirion R. (1996) Are insulin-like growth factor II involved in the uptake of beta amyloid peptide into rat primary hippocampal cultured neurons. Soc. Neurosci. Abstr. 26: 1175.
- 62) Danik, M., Terrisse, L., Dea, D., Poirier, J., and Rassart, E. (1997) Apolipoprotein D increases in rat hippocampus following entorhinal cortex lesioning. Soc. Neurosci. Abstr. 23(1): 89
- 63) Poirier J. (1997) Apolipoprotein E4 as a risk factor in Alzheimer's disease and a predictor of therapeutic efficacy. Conference: Alzheimer's Disease-From Basic Research to Therapeutic Applications. Germany, June 1997.
- 64) Beffert, U., Aumont, N., Dea, D., Davignon, J., and Poirier, J. (1997) Binding, internalization and degradation of apolipoprotein E is increased by amyloid peptides in primary cultures of neurons and astrocytes. Soc. Neurosci. Abstr. 23(1): 537
- 65) Arguin, C., Theroux, L., Danik, M., Dea, D., Charbonneau, B., Gauthier, S., and Poirier, J. (1997) Screening for mutations in the low-density lipoprotein receptor gene in Alzheimer's Disease patients. Soc. Neurosci. Abstr. 23(1): 82
- 66) Sévigny P., Poirier J. and Wiebusch H. (1996) Pharmacogenetic of CNS diseases. Proceedings of the Drug Information Association annual meeting. Montréal, June 1997.
- 67) Poirier, J., Beffert, U., Ramassamy, C., Tremblay, M., Cohn, J.S., Davignon, J., Farlow, M., and Cécylre, D. (1997) Brain levels of apolipoprotein E and apolipoprotein C-III in Alzheimer's Disease. Soc. Neurosci. Abstr. 23(1): 828
- 68) Dea, D., Ramassamy, C., and Poirier, J. (1997) Influence of apoE genotype on brain cholesterol and phospholipid levels in Alzheimer's Disease. Soc. Neurosci. Abstr. 23(2): 1369
- 69) Ramassamy, C., Beffert, U., Averill, D., Christen, Y., Schoofs, A., and Poirier, J. (1997) Influence of apolipoprotein E genotype on lipoperoxidation in Alzheimer's Disease brain. Soc. Neurosci. Abstr. 23(2): 1369
- 70) Auld, D.S., Ramassamy, C., Kar, S., Poirier, J., Gaudreau, P., and Quirion, R. (1997) Neuro-rescuing properties of IGF-I against A β toxicity in vitro: Brain region and trophic factor specificity. Soc. Neurosci. Abstr. 23(2): 1630
- 71) Krzywkowski, P., Gagne J., Chabot, C., Momoli, F., Rochford, J., Massicotte, G., and Poirier, J. (1997) Pharmacology of the cholinergic and glutamatergic systems in behaviorally impaired apoE knockout mice. Soc. Neurosci. Abstr. 23(2): 1905
- 72) Bastianetto, S., Ramassamy, C., Poirier, J., and Quirion, R. (1997) Post-treatment with ginkgo biloba extract (EGB 761) or dehydroepiandrosterone (DHEA) prevents hippocampal cell death induced by hydrogen peroxide in rat. Soc. Neurosci. Abstr. 23(2): 2212
- 73) Champagne, D., Bertrand, P., Gauthier, S., and Poirier, J. (1997) Incidence of herpes simplex virus type 1 DNA in brain of apoE₄ allele carriers: a risk factor for Alzheimer's Disease? Soc. Neurosci. Abstr. Poirier J. (1997) Pharmacogenetic of Alzheimer's disease. IBC Conference, Philadelphia, September 1997
- 74) Poirier J. (1998) Apolipoprotein E as a pharmacogenetic and therapeutic target in Alzheimer's disease. NMHCC Conference, Boston, February. 1998.
- 75) Poirier J. (1998) Is apoE a viable therapeutic target for the treatment of Alzheimer's disease (1998) IBC Conference, Boston, May 1998. 23(2): 2430
- 76) Poirier J. (1998) Pharmacogenetic of Alzheimer's disease. International Conference Bio 98, New York, USA, June 1998.

ABSTRACTS (CONT'D)

- 77) Poirier J.(1998) Apolipoprotein E4 and its impact on the cholinergic system in neurodegenerative diseases. CCNP Annual Meeting, Montréal, Canada. June 1998.
- 78) Poirier J. (1998) Can apolipoprotein E4 help us better understand Alzheimer's disease? Canadian Congress of Neurological Sciences. Montreal, Canada. June 1998.
- 79) Danik M., Arguin C., Thérout L., Beffert U., Dea D., and Poirier J. (1998) Study on the association between two newly identified polymorphism in the LDL receptor gene and Alzheimer's disease. Soc. Neurosci. Abstr. 24: 1219.
- 80) Bastianetto S., Ramassamy C., Christen Y., Poirier J. and Quirion R. (1998) Ginkgo biloba extract (EGB 761) protects in vitro rat hippocampal cells against toxicity induced by b-amyloid peptides. Soc. Neurosci. Abstr. 24: 1456.
- 81) Ramassamy C., Averill D., Theroux L., Lussier-Cacan S., Davignon J., Christen Y. and Poirier J. (1998) Apolipoprotein E genotype influences the antioxidant pattern in Alzheimer's disease brain. Soc. Neurosci. Abstr. 24: 1711.
- 82) Beffert U., Aumont N. and Poirier J. (1998) Pharmacogenetic approach to the treatment of Alzheimer's disease: effect of acetylcholinesterase inhibitors on apolipoprotein E metabolism in vitro. Soc. Neurosci. Abstr. 24: 1712.
- 83) Champagne D., Ghribi O., Dupuy J-B., Aumont N., Rochford J., Massicotte G. and Poirier J. (1998) Neurophysiological and behavioral effects of chronic infusion of human recombinant apolipoprotein E (apoE) in apoE knockout mice. Soc. Neurosci. Abstr. 24: 1713.
- 84) Krzywkowski P., Ramassamy C., Averill D., Lussier-Cacan S., Davignon J., Christen Y. and Poirier J. (1998) Impact of apolipoprotein E deficiency on oxidative stress. Soc. Neurosci. Abstr. 24: 2136.
- 85) Poirier J. (1998) Apolipoprotein E: A pharmacogenomic and therapeutic target for the treatment of Alzheimer's disease. Proceeding of the American College of Neuropsychopharmacology. p 67.
- 86) Poirier J. (1999) Pharmacogenetic approach to the treatment of Alzheimer's disease: a role for apolipoprotein E polymorphism. Proceeding of 10^{ième} Congrès de la Fondation Nationale de Gériologie, France, p 21.
- 87) Poirier J. (1999) Pharmacogenomic approach to the treatment of Alzheimer's disease : A role for apolipoprotein E polymorphism. Proceeding of the 8th IBC Annual Conference on Alzheimer's Disease Boston, USA. p. 36.
- 88) Dupuis J.B., Champagne D. , Poirier J. and Rochford J. (1999) ApoE-knockout mice: do they display cognitive deficits? Soc. Neurosci. Abstr. 25: 28
- 89) Petit-turcotte C., Beffert U., Cohn J.S., Schacter N. and Poirier J. (1999) Cerebral expression of apoC-I and apoC-III decreases in Alzheimer's disease, yet not influenced by apoE genotype. Soc. Neurosci. Abstr. 25: 542
- 90) Aumont N., Kar N., Pearson D., Champagne D., Quirion R. and Poirier J. (1999) : Elevation of & beta; amyloid peptides is related to synaptogenesis and spatial memory performance in aged rats. Soc. Neurosci. Abstr. 25: 818.
- 91) Poirier J., Panisset M., Ramassamy C., Dea D and Aumont N. (2000) Apolipoprotein E: A therapeutic target for the treatment of Alzheimer's disease. Proceedings of the 7th International Springfield Symposium on Alzheimer's disease. p 125.
- 92) Dea D., Aumont N. and Poirier J. (2000) Apo E and apo E receptor gene expression in the brain of Alzheimer's disease subjects with different apoE genotype. Proc. World Alzheimer Congress 2000. p 518.
- 93) Poirier J. (2000) Apo E as a therapeutic target for the treatment of Alzheimer's disease. Proceedings of World Alzheimer Congress 2000. p 626.

- 94) Petit-Turcotte C., Beffert U., Shachter N.S., Cohn J.S., Aumont N. and Poirier J. (2000) Cerebral expression of apoE and apoC-1 in Alzheimer's disease in relation to E4 and H2 polymorphic alleles. Proceedings of World Alzheimer Congress 2000. p 930.
- 95) Apolipoprotein E: A pharmacogenetic and therapeutic target for the treatment of Alzheimer's disease Jannssen Medical Institute, Goteborg, Sweden, September 2000 (Guest of Janssen Institute)
- 96) Vaucher E. Aumont N., Pearson D., Rowe W., Poirier J., Quirion R. and Kar S. (2000) Amyloid B peptide levels and its effects on hippocampal acetylcholine release in aged, cognitively-impaired and -unimpaired rats Soc. Neurosci. Abstr. 26: 276.
- 97) Champagne D., Rochford J. and Poirier J. (2000) ApoE and LDL receptor knockout mice display acquisition deficits in the Morris water maze. Soc. Neurosci. Abstr. 26: 575.
- 98) Valastro B., Ghribi B., Poirier J., Krzywkowski P. and Massicotte G. (2000) AMPA receptor regulation and LTP in the hippocampus of young and aged apolipoprotein E-deficient mice. Soc. Neurosci. Abstr. 26: 665.
- 99) Poirier J. and Panisset M. (2001) Apolipoprotein E: A novel therapeutic target for the treatment of Alzheimer's disease. in the Proceeding of the 5th International conference in Alzheimer's and Parkinson's disease. p.11.
- 100) Poirier J. (2001) Apolipoprotein E : a pharmacogenomic and therapeutic target for the treatment of Alzheimer's disease. Clin. Chem. 47: S6 : p. 10.
- 101) D. Dea; L. Lamarre-Theroux; N. Aumont; and Poirier J. (2001) Abnormal splicing of the 3-hydroxy-3-methylglutaryl coenzyme A reductase in the brain of sporadic Alzheimer's disease subjects. Soc. Neurosci. Abstr. # 192.5.
- 102) N. Aumont, Dea D., Lamarre-Theroux L., Beffert U. and J. Poirier (2001) Decreased HMG-Coa Reductase activity in AD patients is associated with high levels of beta-amyloid. Soc. Neurosci. Abstr. # 192.6.
- 103) D. Champagne, D.- Pearson, D. Dea, J. Rochford and J. Poirier (2001) Chronic treatment with probucol increases apoE level in the hippocampus of aged rats and improves reference memory in the Morris water maze. Soc. Neurosci. Abstr. # 201.1.
- 104) Gaudreault S., J.F. Blain; D. Champagne; C. Casanova; J. Poirier (2001) Overexpression of caveolin-1 in hippocampus correlates with the onset of reactive synaptogenesis. Soc. Neurosci. Abstr. # 390.4.
- 105) Blain J.F., D. Champagne; E.H. Vaucher; I. Reymond-Marron and J. Poirier (2001) Cholesterol homeostasis in response to injury in the mouse brain. Soc. Neurosci. Abstr. # 752.8.
- 106) Ramassamy C., J. Poirier; M.-G. Martinoli and Y. Christen (2001) Inhibition of B-amyloid fibril formation by the ginkgo biloba extracts EGB 761 and CP205. Soc. Neurosci. Abstr. # 921.19.
- 107) Poirier J. (2002) Cholesterol lowering agents and HMG CoA reductase gene expression in sporadic Alzheimer's disease. Proceedings of the 8th International Springfield Symposium on Alzheimer's disease. p.102.
- 108) Poirier J. (2002) Cholesterol transport and synthesis in the pathophysiology of Alzheimer's disease Proceedings of World Alzheimer Congress 2002. Neurobiol Aging 23: S564.
- 109) Poirier J. (2003) Apolipoprotein E and cholesterol metabolism in the pathophysiology and treatment of Alzheimer's disease. Proceedings of International Alzheimer's and Parkinson's diseases Congress, 2003. pp. 106.
- 110) Poirier J. (2003) Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Proceedings of the Neurobiology of Aging Symposium, New Orleans, p.68.
- 111) Poirier J., Panisset, M, Thérroux L., Aumont N. and Dea D. (2004) Apo E Induction and Cholesterol Lowering Strategies In The Treatment of Sporadic Alzheimer's Disease. Neurobiol. Aging. 25 (S1): 20.
- 112) Blain J.F. and Sullivan P., and Poirier J. (2004) Genotype specific alterations in response to entorectal cortex lesions in human apolipoprotein E targeted replacement mice. Neurobiol. Aging. 25 (S1):21.
- 113) Blain J.F. and Sullivan P., and Poirier J. (2004) Response to Brain Injury in Human Apolipoprotein E

- Targeted Replacement Mice is Genotype-Specific. Proceeding of the 9th International Conference of Alzheimer's Disease and Related Disorders, Philadelphia, p. 85.
- 114) Poirier J. (2005) ApoE and HMG CoA Reductase: Genetic Risk Factors and Therapeutic Targets for Sporadic Alzheimer's Disease. Proceedings of International Alzheimer's and Parkinson's diseases Congress, Sorrento, Italy, 2005. pp. 43.
 - 115) Poirier J. (2005) Apolipoprotein E4: A target for developing new therapeutics for Alzheimer's disease. Proceeding of the International Conference on Cholesterol, Statins and Alzheimer's disease, Stockholm, Sweden, 2005. p. 5.
 - 116) Poirier J. (2006) Targeting ApoE and HMG CoA Reductase in sporadic Alzheimer's disease. Neurobiol. Aging 27: 17 and in the proceedings of the 10th International Springfield Symposium on Alzheimer's disease in Geneva.
 - 117) Poirier J. (2006) Targeting apolipoprotein E and HMG CoA reductase for the treatment of sporadic Alzheimer's disease. Proceeding of the 10th International Conference of Alzheimer's Disease and Related Disorders, Madrid, Spain. p.56.
 - 118) Leduc V., Dea D., Thérroux L. and Poirier J. (2007) Apolipoprotein E4 and Paraoxonase 1 genetic variations affect both risk levels and cholinergic system integrity in the human brain with Alzheimer's disease. Proceedings of the 8th International Conference of Alzheimer's Disease and Parkinson's disease Austria, p.16.
 - 119) Leduc V., Dea D., Thérroux L. and Poirier J. (2007) Paraoxonase 1 genetic variations affect both risk level and cholinergic system integrity in the human brain with Alzheimer's disease, Soc. Neurosci. Abstr. #795.22
 - 120) Pearson V., Bélanger S., Dea D., Thérroux L. (2007) ABC Transporters ABCA1 and ABCG1 in the regulation of cholesterol homeostasis during synaptic remodelling in the mice. Soc. Neurosci. Abstr. #260.4
 - 121) Bélanger S. Pearson V., Dea D. and Poirier J. (2007) Role for PCSK9 in regulating brain cholesterol metabolism during synaptic remodelling in the adult mice. Soc. Neurosci. Abstr. #16.9.
 - 122) Poirier J. (2008) Perspective on the role of public / private partnerships in the development of novel experimental therapies for Alzheimer's disease. Leon Thal Symposium., USA.
 - 123) Fiocco A., Nair N.P.V., Lupien S and Poirier J. (2007) The influence of genetic polymorphism on cortisol, cognition, and psychological factors in older adults. Biol. Psych. 61: 8: 216.
 - 124) Fiocco A., Nair N.P.V., Joobar R., Poirier J., Lupien (2008) A Genetic Interaction Between APOE and BCHE on Basal and Reactive Cortisol Secretion in a Sample of Older Adults from the Baby Boomer Generation, Endocrine Society's 90th Annual Meeting, San Francisco.
 - 125) Poirier J. (2009) HMG CoA reductase is a genetic modifier for risk, age of onset and neurofibrillary tangles accumulation in Alzheimer's disease. Proceedings of the 9th International Conference of Alzheimer's Disease and Parkinson's disease. Prague, Czech Republic, p.7.
 - 126) Belanger Jasmin S., Theroux L, Dea D., Poirier J. (2009) Pcsk9 Genetic Variants And Alzheimer's Disease Risk. . Proceedings of the 9th International Conference of Alzheimer's Disease and Parkinson's disease. Prague, Czech Republic, p. 49.
 - 127) Poirier J. Dea D., Leduc V. and Theroux L.(2009) HMG CoA reductase: Gene risk factor and modulator of Alzheimer's disease pathology. Proceedings of the 9th International Conference of Alzheimer's Disease and Parkinson's disease. Prague, Czech Republic, p. 14.
 - 128) Poirier J., Dea D. and Thérroux L., Petersen R. Aisen P. and the ADCS (2010) Butyrylcholine esterase pharmacogenomics in MCI, in: Proceeding of the 11th International Conference of Alzheimer's Disease and Related Disorders, Hawaii, USA, J. Alz. Dement. S99.
 - 129) Dea D., Thérroux L., Legault V., Leduc V. and Poirier J (2010) HMG CoA reductase as a modulator on Alzheimer's disease pathology in: Proceeding of the 11th International Conference of Alzheimer's Disease and Related Disorders, Hawaii, USA, J. Alz. Dement. S191.
 - 130) Thérroux L., Dea D., Leduc V. and Poirier J (2010) Involvement of paraoxonase 1 (PON1) genetic variants in Alzheimer's disease pathology in: Proceeding of the 11th International Conference of

-
- Alzheimer's Disease and Related Disorders, Hawai, USA, J. Alz. Dement. S196.
- 131) Domenger D., Moquin L., Gratton A, Dea. D., Th  roux L, Breitner J. and Poirier J. (2011) Reinnervation mechanisms in Parkinson's disease : A Role for Apolipoprotein E ? Proceedings of the 10th International Conference of Alzheimer's Disease and Parkinson's Disease. Barcelona, Spain, p. 76.
 - 132) De Beaumont L., Tremblay S. and Poirier J. (2011). Synergistic Effects of Genetics and Sports Concussions in Aging. J. Alz. Dem. 7 (4) : S183.
 - 133) Poirier J, Y.S. Tsantrizos, J.W. De Schutter 2, Y.-S. Lin, P. Gormley, L. Th  roux and D. Dea (2013) Isoprenoid Pathway as a Therapeutic Target for Common Alzheimer's Disease. Proceedings of the 11th International Conference of Alzheimer's Disease and Parkinson's disease. Florence, Italy.
 - 134) Poirier J. (2013) Genomics of Unhealthy Aging: Clues from Alzheimer's disease. Proceedings of the 21st International Congress on Genetics. Singapore, Singapore. Page A7.
 - 135) Poirier J. (2013) Apolipoprotein E, Cholesterol and Cardiovascular Factors in the Etiology of Alzheimer's Disease: Myths and Reality. Proceedings of the International Conference on Nutrition and the Brain. Washington, USA.

Patents Portfolio

"Apolipoprotein E Polymorphism and Treatment of Alzheimer's Disease", which patents or patent applications claim the priority and benefit of Canadian patent application 2,111,503, International Patent Application PCT/CA94/00681, British Provisional patent application 1770-119 GB and International Patent Application PCT/CA/95/00240.

Country	Status	Number
United States	Granted	5935781
United States divisional	Pending	09/342993
Canada	Granted	2188933
France	Pending	Not available
Great Britain	Pending	Not available
Germany	Pending	69531557.9-08
Finland	Pending	964284
Japan	Granted	3285585
Australia-1	Granted	693193
Australia-2	Granted	733237
New-Zealand-1	Granted	284412
New Zealand-2	Granted	500375
Singapore	Granted	34770

"Pharmacogenetic Methods in the Treatment of Nervous System Diseases", which patents or patent applications claim the priority and benefit of international patent application WO9827227 filed December 12, 1997 which application claims the priority and benefit of U.S. application number 1996000766975 filed December 12, 1996.

Country	Status	Number
United States-1	Granted	6022683
United States-2 divisional	Pending	09/500162
Australia	Granted	745073
Canada	Pending	2275504
Europe	Allowed	97953011.0
Japan	Pending	10-527507

"Method for Determining the Prognosis of a Patient with a Neurological Disease", which patents or patent applications claim the priority and benefit of international patent application WO98/27226 filed December 16, 1997 which application claims the priority and benefit of U.S. application number US 1996000766975 filed December 16, 1996.

Country	Status	Number
United States 1	Granted	6251587
United States-2	Pending Notice of Appeal	09/548540
Canada	Pending	2275404
Europe	Allowed	97953011.0

"Methods for Treating a Neurological Disease by Determining BCHE Genotype", which patents or patent applications claim the priority and benefit of international patent application WO 99/66072 filed June 16, 1999 which application claims the priority and benefit of U.S. application number US 1998000089406P (U.S. provisional 60/089,406) filed June 16, 1998.

Country	Status	Number
United States	Granted	6291175
Canada	Granted	2330829

Country	Status	Number
Australia	Granted	45292/99
Germany	Granted	69929787
Japan	Granted	2000-554880
Europe	Granted	EP1088104

"Genotyping of the Paraoxonase 1 Gene for Prognosing, Diagnosing, and Treating a Disease", which patents or patent applications claim the priority and benefit of international patent application WO 01/07644 filed July 19, 2000, which application claims the priority and benefit of U.S. application number US US199900001145602P (U.S. provisional 60/145,602) filed July 26, 1999.

Country	Status	Number
United States	Granted	6,573,049
Europe	Granted	EP 1 208 233B1

"Methods for Increasing ApoE levels for the Treatment of Neurodegenerative Disease" which patent or patent application claims the priority (Sept. 24, 1998) and benefit of provisional application 09/160,462 filed on September 24, 1997.

Country	Status	Number
United States	Granted	6,274,603

" Method for detecting a neuropathology by measuring apolipoprotein D" which patent or patent application claims the priority and benefit of provisional application 09/087,769 filed on September 12, 1999. Co-inventors: Terisse L., Rassart E. and Poirier J.

Country	Status	Number
Canada	Granted	2,333,946
PCT	Pending	WO9963350

"Hydroxymethylglutaryl CoA reductase and Diagnosis and Prognostication of Dementia which patent or patent application claims the priority and benefit of provisional U.S. provisional application 2005/0069881 A1 filed on March 31, 2005.

Country	Status	Number
United States	Pending	10/487,747

"Genetic Profile of the Markers Associated with Alzheimer's Disease" which patent or patent application claims the priority and benefit of provisional U.S. provisional application 61/108,170 filed on October 24, 2008
 Inventors: BELOUCHI ABDELMAJID [CA]; RAELSON JOHN VERNER [CA]; POIRIER JUDES [CA]; PAQUIN BRUNO [CA]; KEBACHE SEM [CA]; DEBRUS SOPHIE [CA]; VAN EERDEWEGH PAUL [US]; CROTEAU PASCAL [CA]; SEGAL JONATHAN [IL]; LITTLE RANDALL DAVID [CA]; KEITH TIM [US] + (BELOUCHI, ABDELMAJID, ; RAELSON, JOHN VERNER, ; **POIRIER, JUDES**, ; PAQUIN, BRUNO, ; KEBACHE, SEM, ; DEBRUS, SOPHIE, ; VAN EERDEWEGH, PAUL, ; CROTEAU, PASCAL, ; SEGAL, JONATHAN, ; LITTLE, RANDALL DAVID, ; KEITH, TIM).

Country	Status	Number
United States	Pending	61 / 108170

"Bisphosphonate Inhibitors that Modulate Intracellular Phospho-Tau Levels in Neurons" which patent or patent application claims the priority and benefit of provisional U.S. provisional application filed on Nov 29, 2011.

Inventors: Youla S. Tsantrizos, Judes Poirier, Joris De Schutter and Yih-Shyan Lin

Country	Status	Number
United States	Pending	ADN 05001770-472USPR

Career Highlights:

- June 1993 Our team discovered the function of the so-called apolipoprotein E (apoE) in the mature brain and its role in the coordination of reinnervation in the disease or injured CNS. However, when fellow colleague Alan Roses at Duke and our group in Montreal identified the apoE4 variant as a common genetic risk factor for the common form of Alzheimer's disease in humans, it became clear that the number of alleles one inherits from his parents influences risk level, age of onset and the rate of progression of this terrible disease.
- December 95 Our team published a revolutionary study in which we revealed that the apoE gene also compromised markedly the efficacy of the only drug available (at the time) for the treatment of Alzheimer's disease. The drug, referred to as a memory enhancer, was commercialized by Warner Lambert (now Pfizer). This important finding was prominently featured in a December 1995 issue of Wall Street Journal as a landmark discovery of the human genome project era. This became known as "one of the pivotal steps in development of the so-called personalized medicine for brain diseases" according to Francis Collins's N.E.J.M. 1997 review paper on the human genome project endeavor.
- 1995-1996 During the same period, our work was featured on three different occasions by the Institute for Scientific Information in Philadelphia (USA) who tracks the scientific impact of novel medical discoveries around the world (independent US-based assessor of scientific impact). The "Hot List" recognizes the most important research discoveries in the field of medicine on a monthly basis. Our work was listed among the "Top 10" most important medical discoveries in January 1995, May/June 1996 and again in January 1997. Actually, our team became one of the most cited Canadian teams in the field of medicine during that period. We used this unique opportunity to file several patents worldwide on the topic of gene / drug interactions. Our team is also member of the select top 20 research breakthroughs of the decade (1992-2002) according to the ISI, in the field of Alzheimer's disease.
- January 1996 As principal investigator, I was named one of the ten "Personality of the Year" by the magazine l'Actualité (Québec's equivalent to the Maclean Magazine) among a few other nominees that included Céline Dion and Guy St-Pierre (Chairman of the Board, Royal Bank).
- June 1996 We then convinced McGill, the MDS Health Venture Fund from Toronto and a few angel investors from the province of Québec to create the first Canadian biotechnology corporation based on gene/drug interaction (pharmacogenomics). The company called Nova Molecular Inc. was built around our intellectual properties and technological platform. While in operation between 1996-2004, Nova Molecular obtained contracts from international pharmaceutical corporations such as Parke Davis (Warner Lambert), Pfizer, Bayer, Novartis, Hoffman Laroche, Eli Lilly, Servier as well as from smaller biotech corporations such as Neotherapeutic, Voyager and Ebewe (Austria). Nearly all clinical drug trials performed in dementia in the past 12 years have performed apoE pharmacogenomic profiling, some of which led to spectacular findings (see Pfizer's Aricept in mild memory impaired subjects, N.E.J.M. summer 2005).
- 1999 At the American Neuropsychopharmacology meeting in December 1999, Dr. Poirier presented the first series of findings on a new treatment strategy based on the role of apoE in brain repair. Apolipoprotein E is found in abnormally low concentration in the brain of Alzheimer's disease subjects that are carriers of the apoE4 variant. Dr. Poirier discovered that an old cholesterol lowering medication called Probucoil is capable of reversing the apolipoprotein E deficit in the brain of a small cohort of Alzheimer subjects and can significantly improve the quality of life of those patients within only six months of treatment. This turned out to be his third breakthrough discovery in less than 6 years.
- 1999-2012 Dr. Poirier has maintained an excellent productivity in the field of research while extending his research on drugs capable of inducing apoE synthesis and secretion in the mature brain. He recently teamed-up with Canadian Philanthropists to raise money for the creation of a new biopharmaceutical corporation called Spectral Neuroscience Inc. dedicated to the development and optimization of an apoE-based treatment. In partnership, with Genizon Bioscience and Pfizer Pharmaceutical, he recently completed

the first Genome Wide Association Studies in Alzheimer's disease subjects born in a unique population isolate from eastern Canada while led to the discovery of 6 novel genetic risk factors for the common form of Alzheimer's disease. His team is actively examining the function of these new genes in the normal and diseased brain to better understand their implication in the initiation of the disease process. These past 5 years, all the different Alzheimer clinical drug trials performed by mid-size to large pharmaceutical corporations around the world have included routine apoE4 genetic profiling for all recruited subjects; a testimony of the marked impact that our discoveries has in the field of drug/gene interaction. In 2004, he was named "Knight of the Order of Quebec" by the Premier for his outstanding contribution in the field of Alzheimer's disease both, locally and internationally.